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RIASSUNTO 
 
I foldameri sono oligomeri di sequenza specifica simili a peptidi, proteine ed 
oligonucleotidi che si ripiegano in strutture tridimensionali ben definite.1 Elementi 
strutturali per la costruzione dei foldameri sono composti come i -peptidi, le 
oligouree ed i composti aromatici.2 Anche se gli studi sui foldameri all‘inizio erano 
maggiormente indirizzati verso la comprensione dei fattori che governano il loro 
ripiegamento, in seguito sono stati sviluppati alcuni foldameri con proprietà 
biologiche molto interessanti.3 Ispirati dagli sviluppi di questo campo di ricerca, 
abbiamo progettato foldameri costruiti mediante l‘uso di mimetici di ripiegamenti di 
tipo beta che sono stati selezionati mediante dinamica molecolare per la loro 
propensione ad adottare strutture organizzate quando oligomerizzati.2 Fra i vari 
motivi strutturali selezionati dal programma di dinamica molecolare, due mimetici di 
-turns, il (3S)[ammino]-5-(carbossimetil)-2,3-diidro-1,5-benzotiazepin-4(5H)-one o 
DBT4 e l‘acido 2-amminometil-fenil-acetico o AMPA (Figura R.1) sono stati scelti 
come elementi strutturali per la loro propensione ad adottare strutture elicoidali in-
silico e per la loro facilità di sintesi. 
 
 
Figura R.1 Mimetici di b-turns: le strutture di (3S)-amino-5-(carboxylmethyl)-2,3-dihydro-1,5-
benzothiazepin-4(5H)-one o DBT ed il l’acido 2-amminometil-fenil-acetico o AMPA 
 
E‘ stata prima di tutto sviluppata una strategia di sintesi per l‘ottenimento di 
grandi quantità di DBT N-protetto mediante il gruppo protettore 9-
fluorenilmetossicarbonile (Fmoc). Questa sintesi ha permesso di ottenere dopo 
diversi stadi più di 25 grammi di Fmoc-DBT-OH con una resa globale di circa il 50%. 
L‘AMPA é stato invece comprato e poi protetto con Fmoc. Gli ammino acidi non-
naturali protetti mediante il gruppo Fmoc così ottenuti sono stati usati come 
monomeri di partenza per la costruzione di oligomeri mediante una sintesi peptidica 
di tipo standard in fase solida (SPPS). Il nostro primo obiettivo è stato quello di 
eseguire un‘analisi strutturale degli oligomeri mediante NMR, dicroismo circolare e 
diffrattometria a raggi-X. Sono stati sintetizzati oligomeri di diversa lunghezza protetti 
all‘N-terminale mediante acetilazione o mediante il gruppo 2-bromobenzilossicarbonil 
Z(Br) (Figura R.2) per gli studi di cristallizzazione al fine di ottenere cristalli singoli da 
usare in diffrattometria. Esempi degli oligomeri sintetizzati per gli studi strutturali sono 
riportati nella Tabella R.1. 
 
Tabella R.1. Esempi di oligomeri sintetizzati per studi strutturali 
Composti Analisi strutturali 
Ac-(DBT)n-NH2 ; n=[1-8] NMR e cristallizazione 
Z(Br)-(DBT)n-NH2 n=[4-5] Cristallizzazione 
Ac-DBT-LBT-DBT-LBT-NH2 NMR e cristallizazione 
Ac-(AMPA)n-NH2 n=[4-5] NMR e cristallizazione 
2 
 
 
Figura R.2 Sintesi generale in fase solida (SPPS) di oligomeri DBT protetti mediante il 
gruppo Z(Br) all’amino terminale per saggi di cristallizzazione, mediante il gruppo acetile per 
studi strutturali di NMR e mediante fluoresceina per i saggi di internalizzazione. Lo stesso 
approccio sintetico è stato usato per la sintesi degli oligomeri di AMPA 
 
Tutti i composti sono stati purificati mediante cromatografia preparativa HPLC 
e sono stati ottenuti con purezza molto elevata (>98%) ed infine caratterizzati 
mediante LC-MS. Sono state anche utilizzate tecniche NMR 1D e 2D per 
caratterizzare la struttura dei composti. Sono state evidenziate nelle varie molecole 
numerose interazioni a lunga distanza mediante esperimenti 2D ROESY e 2D 
NOESY. L‘insieme di tutti questi dati suggerisce fortemente un‘organizzazione 
strutturale ben definita degli oligomeri Ac-DBT5-NH2 ed Ac-DBT6-NH2. Piccoli cristalli 
delle stesse molecole sono stati ottenuti ma al momento la loro grandezza non risulta 
sufficiente per studi cristallografici mediante diffrazione dei raggi-X. 
 
In uno studio parallelo è stato ipotizzato che piccoli oligomeri ottenuti dagli 
elementi strutturali di DBT o di AMPA potessero traslocare la membrana cellulare ed 
essere usati come nuova classe di non-peptidi che penetrano la cellula (cell 
penetrating non-peptides, CPNP).5,1 Anche se questi peptidi non presentano carica 
come la maggior parte dei peptidi cell-penetrating, CPP6 o i CPNP, si è considerato 
che in virtù della loro aromaticità, idrofobicità e struttura ben organizzata potessero 
avere interazioni non-specifiche con il doppio strato lipidico e perciò essere 
internalizzati nella cellula. Gli oligomeri corti sono stati sintetizzati su una resina Rink 
ammidica a cui è seguita la metodologia di sintesi in fase solida SPPS e 
successivamente fluorescinati all‘N-terminale con fluoresceina isotiocianato (Figura 
R.2). Inizialmente l‘uptake cellulare in cellule cancerose della mammella MDA-MB-
231 di oligomeri tipo (DBT)2-4 è stato analizzato mediante misure di emissione di 
fluorescenza (Figura R.3) e confrontate come controllo positivo al ben noto e potente 
CPP octarginina (Arg8)
7 e come controllo negativo alla carbossifluoresceina (CF). La 
maggiore intensità di fluorescenza intracellulare è risultata essere quella di DBT4 con 
un drastico decremento (>4 volte) per gli oligomeri DTB3 e DTB2  (Figura R.3).
8 
Quindi l‘uptake cellulare sembrava essere dipendente dalla lunghezza aumentando 
l‘internalizzazione con la grandezza dell‘oligomero. Inoltre la quantità di DBT4 che era 
internalizzata era più significativa di quella di Arg8 nonostante il fatto che DBT4 non 
sia carico. Mediante microscopia confocale è stato stabilito che i nostri composti 
sono essenzialmente localizzati negli endosomi dopo 3 ore di incubazione e nei 
3 
 
liposomi dopo 16 ore di incubazione. In conclusione questi dati indicano l‘abilità di 
questi oligomeri di essere internalizzati mediante un meccanismo endolisosomiale. 
 
 
Figura R.3. Determinazione dell’internalizzazione dei composti dopo 3 ore di incubazione a 
37°C e a concentrazione di composto fluoresceinato 10-5 M. 
 
Anche se molti degli studi iniziali di drug delivery erano tesi ad evitare come 
obiettivo i lisosomi onde prevenire la successiva degradazione della molecola, studi 
più recenti hanno dimostrato la rilevante utilità clinica dell‘uso di questo 
compartimento cellulare per la drug delivery nel trattamento di disturbi dell‘accumulo 
nei lisosomi, nel morbo di Alzheimer e nel cancro.9 
 
Nell‘analizzare l‘efficienza dell‘internalizzazione dei nostri CPNP si è deciso di 
valutare direttamente la loro concentrazione all‘interno della cellula. Anche se sono 
stati impiegati diversi metodi di individuazione dell‘uptake cellulare di composti che 
penetrano in cellula come i coloranti fluorescenti o composti radioattivi, i risultati 
differiscono fortemente da uno studio all‘altro a seconda del protocollo utilizzato ed in 
tutti i casi la quantificazione rimane difficile. Uno studio riportato da Burlina et al.10 ha 
portato un grande miglioramento nel proporre un metodo quantitativo altamente 
riproducibile basato su MALDI-TOF MS per misurare la concentrazione del peptide 
internalizzato. Tuttavia, dopo la lisi cellulare, questo metodo richiede la cattura del 
CPP cui è legata la biotina da parte di granuli magnetici ricoperti di streptavidina. 
Questo stadio è particolarmente critico per l‘accuratezza della quantificazione. 
Questo è il motivo per il quale si è deciso di sviluppare una nuova metodologia di 
carattere generale basata sulla spettrometria MALDI-TOF MS che non richieda 
alcuna purificazione o stadi di separazione. Si è studiata l‘internalizzazione di 
composti CPP/CPNP marcati con l‘acido -ciano-4-idrossicinnamico (HCCA) 
seguendo i segnali in una matrice neutra dell‘estere metilico dell‘acido -ciano-4-
idrossicinnamico (HCCE) (Figura R.4 B). Questa matrice combinata (HCCA legato e 
HCCE) ha permesso di discriminare i segnali MS indotti dal peptide di interesse che 
erano presenti in bassa concentrazione da quelli dei peptidi non marcati molto 
abbondanti. Per aggiunta di precise quantitá di CPP/CPNP marcati con HCCA 
deuterato (Figura R.4 A) prima dell‘esperimento MALDI-TOF MS, il CPP/CPNP 
internalizzato può essere quantificato sulla base del rapporto fra i picchi [M+H]+ del 
CPP deuterato e quello non deuterato etichettato con HCCA (Figura R.4 B).11 
4 
 
 
 
Figura R.4 A) Sintesi dei CPP con HCCA non marcato (Do) e marcato con deuterio (D4). B) 
Strategia per la diretta quantificazione dell’uptake cellulare dei CPP (e un CPNP) mediante 
MALDI-TOF MS con l’uso dell’effetto di discriminazione HCCA/HCCE: a) incubazione delle 
cellule con CPP marcato con HCCA; b) stadio di lavaggio; c) stripping enzimatico della 
membrana cellulare; d) lisi cellulare, seguita dall’aggiunta di un ammontare preciso del CPP 
deuterato e marcato con HCCA come standard interno; e) analisi MALDI-TOF dell’intero 
lisato cellulare nella matrice HCCA; f) analisi MALDI-TOF dell’intero lisato cellulare nella 
matrice “neutra” HCCE. L’effetto di discriminazione dei segnali HCCA/HCCE produce un 
aumento del segnale del CPP nella miscela complessa. Il CPP internalizzato può essere 
quantificato sulla base del rapporto fra i picchi [M+H]+ del CPP deuterato e di quello non 
deuterato marcato con HCCA. Boc = tert-butossicarbonilo, DIEA = N,N-
diisopropiletilammina, HBTU = O-(benzotriazol-1-il)-N,N,N’,N’-tetrametiliuronio 
esafluorofosfato, TFA = acido trifluoroacetico, TIS = triisopropilsilano. 
 
Un altro aspetto molto interessante della ricerca è stato quello riguardante la 
sintesi di bioconiugati fra i nuovi CPNP ed alcuni composti biologicamente attivi 
capaci di per se di attraversare la membrana cellulare. A tale scopo abbiamo scelto 
un potente inibitore dell‘enzima catepsina D (CD), cioè la pepstatina. La catepsina D 
è una aspartico endopeptidasi lisosomiale solubile, sintetizzata nel reticolo 
endoplasmatico sotto forma di preprocatepsina D (pCD). pCD è una glicoproteina 
con due oligosaccaridi legati all‘azoto bersaglio di strutture intracellulari vescicolari 
(lisosomi, endosomi, fagosomi).12 Entrando nei compartimenti acidi endosomiali e 
lisosomiali si ottiene idrolisi proteolitica del pCD con formazione della forma 
enzimatica attiva della CD. In normali condizioni fisiologiche pCD è smistato ai 
lisosomi e si trova nella cellula, ma in alcune condizioni patologiche fisiologiche come 
il cancro pCD/CD sfugge al normale meccanismo e viene secreto dalla cellula. Una 
volta secreto all‘esterno pCD può essere internalizzato per endocitosi via M6PR o da 
recettori ancora sconosciuti da entrambe le cellule cancerose e dai fibroplasti. Il pCD 
endocitosato va a maturazione dando luogo a CD attiva enzimaticamente. Un‘attività 
extracellulare della CD o all‘interno degli endosomi può essere responsabile 
dell‘attivazione di diversi fattori di crescita e di recettori di fattori di crescita. Inoltre 
CD digerisce varie chemochine e può perciò attenuare la risposta immunitaria anti-
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tumorale. Vari gruppi hanno dimostrato che la crescita tumorale non è inibita dal 
potente inibitore di CD pepstatina. La pepstatina anche se è un inibitore molto 
potente nello stato di transizione della CD è tuttavia incapace di attraversare la 
membrana cellulare. Inoltre l‘attività della pepstatina in vitro ed in vivo è impedita 
dalla sua scarsa solubilità in acqua. Perciò se si può escludere l‘importanza 
dell‘attività enzimatica di CD al di fuori della cellula, rimane la possibilità di 
un‘attivazione specifica dei fattori di crescita all‘interno dei lisosomi o endosomi. 
Sono stati sintetizzati vari coniugati CPNP-pepstatina e saggiati in vitro per la loro 
capacità di inibizione della crescita di cellule MDA-MB-231 del tumore della 
mammella. Alcuni di questi coniugati mostrano un‘alta tossicità, probabilmente 
susseguente l‘inibizione della catepsina D negli endosomi. Uno dei più potenti 
composti investigati in tal senso è risultato essere JMV4463 (Figura R.5). Questo 
composto è stato ottenuto dalla coniugazione della pepstatina con AMPA4 per la 
parte che localizza gli endosomi e per la parte responsabile della solubilità ad un 
derivato del glicol polietilenico e da un residuo di D-arginina. Si è così ottenuto una 
pepstatina vettorizzata che è allo stesso tempo solubile in acqua. I buoni risultati in 
vitro ottenuti per questo composto ci incoraggiano per i saggi in vivo da effettuare nel 
prossimo futuro. Abbiamo sintetizzato apprezzabili quantità di JMV4463 per poter 
ottenere sufficiente prodotto per effettuare questi saggi di attività anti-tumorale  su 
ratti. 
 
Figura R.5 Il composto JMV4463 – un composto bioconiugato formato da tre parti. In rosso 
la parte di CPNP (AMPA)4 sviluppata dal nostro gruppo, in blu il potente inibitore della 
catepsina D pepstatina ed in verde la parte responsabile della solubilizzazione. 
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SUMMARY 
 
As a part of a program for foldamer design1 two β-turn mimetics (3S)-amino-5-
(carboxylmethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one or DBT2 and 2-
aminomethyl-phenyl-acetic acid or AMPA were selected as frameworks from a 
molecular modeling study for their suitability to adopt helical structure. At first we 
developed a highly efficient scale up synthesis of the DBT moiety protected by 9-
fluorenylmetoxycarbonyl (Fmoc) group. By standard solid phase peptide synthesis 
(SPPS) we synthesized DBT oligomers of different lenghts and modifications were 
introduced at their N-terminus. Our first task was to perform structural analysis of the 
oligomers by NMR and X-Ray. Numerous NOE interactions in the DBT pentamer and 
hexamer molecules were detected by NMR 2D NOESY experiments. These data 
strongly suggest the organization of these DBT oligomers. Small crystals were 
obtained from the same molecules in DMSO but at the time being their size is not 
important enough for X-Ray crystallography studies. In a parallel study we 
hypothesized that short oligomers constructed by DBT or AMPA frameworks could 
translocate the cellular membrane and could be used as new cell penetrating non-
peptides - CPNP (see section I.2.2).3,4 Even though these compounds are not 
charged as most cell penetrating peptides (CPP)5 or CPNP, we considered that by 
virtue of their aromaticity, hydrophobicity and their well-organized structure they 
could have a non-specific interaction with the lipid bilayer and thus be internalized 
into the cell. Short oligomers were synthesized on Rink amide (RA) resin following 
SPPS methodology and labelled at their N-terminus with fluorescein isothiocyanate 
(FITC). At first the cellular uptake of the (DBT)2-4 oligomers in MDA-MB-231 breast 
cancer cells was analyzed by fluorescence emission measurement and compared to 
the potent and well-studied CPP octa-arginine (Arg)8
6,7 as a positive control and 
carboxyfluorescein as a negative control. The highest intracellular fluorescence 
intensity was found for (DBT)4 with a drastic decrease (>4-times) for (DBT)3 and 
(DBT)2 oligomers.
8 Thus, the cellular uptake appeared length-dependent with an 
increase of the internalization with the oligomer size. Moreover, the amount of (DBT)4 
that was internalized was more significant than that of (Arg)8 despite the fact that it is 
uncharged. By confocal microscopy we determined that (DBT)4 is mainly localized in 
the endosomes after 3 hours of incubation and in the lysosomes after 16 hours of 
incubation. Altogether, these data indicate the ability of these oligomers to target the 
endolysosomal pathway. Although most of the initial drug delivery studies aimed to 
avoid lysosomal addressing to prevent subsequent drug degradation, more recent 
studies demonstrated the relevant clinical utility to target this compartment for drug 
delivery in the treatment of lysosomal storage diseases, Alzheimer‘s disease, and 
cancer.9 
 
While analyzing the internalization efficiency of our CPNP we decided to 
straightforward evaluate their concentration inside the cells. We studied our 
compounds internalization by total fluorescence emission measurement and by 
confocal microscopy (see sections I.2.3) but none of these techniques gave us the 
possibility to determine the exact amount of compound internalized per cell. A study 
reported by Burlina et al.10 brought a great improvement in proposing a highly 
reproducible quantification method based on MALDI-TOF MS to measure the 
concentration of the internalized peptides. However, after cell lysis, this method 
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requires the capture of the biotin-labelled CPP by streptavidin coated magnetic 
beads. This step is particularly critical for the accuracy of the quantification. This is 
the reason why we decided to develop a new general methodology based on MALDI-
TOF mass spectrometry (MS) which does not require any purification or separation 
steps. We studied the internalization of CPP/CPNP compounds by using an UV light-
absorbing tag -cyano-4-hydroxycinnamic acid (HCCA) and preparing the samples in 
a neutral matrix such as -cyano-4-hydroxycinnamic methyl ester (HCCE). This 
combination (HCCA tag and HCCE matrix) enabled us to discriminate MS signals 
induced by peptides of interest that were present in low concentration from those of 
unlabelled more abundant peptides. By addition of a precise amount of deuterated-
HCCA-tagged CPP/CPNP prior the MALDI TOF MS experiment, the internalized 
CPP/CPNP could be quantified on the basis of the ratio between the [M+H]+ peaks of 
the deuterated and nondeuterated HCCA-tagged CPP.11  
 
Another direction for research was to synthesize bioconjugates between our 
newly discovered CPNP and some biologically active compounds that are unable to 
cross the cell membrane. We selected pepstatine which is a powerful transition state 
inhibitor of the Cathepsin D (CD). Pepstatine while a very potent inhibitor of the CD is 
unable to cross the cellular membrane. Moreover pepstatine activity in vitro or in vivo 
is hampered by its poor solubility in water. CD is a soluble lysosomal aspartic 
endopeptidase synthesized in rough endoplasmic reticulum as preprocathepsin D 
(pCD).12 Upon entering the acidic endosomal and lysosomal compartments 
proteolytic cleavages of the pCD result in the formation of the active enzymatic form 
of CD. Under normal physiological conditions pCD is sorted to the lysosomes and 
found intracellularly but in some pathological and physiological conditions like cancer 
pCD/CD escape the normal targeting mechanism and is secreted from the cell. Once 
secreted to the outside, pCD can be endocytosed via M6PR or yet unknown receptor 
by both cancer cells and fibroblasts. The endocytosed pCD undergoes maturation 
into the enzymatically active CD. An enzymatic activity of CD outside of the cell or 
inside the endosomes could be responsible for the activation of several growth 
factors and growth factor receptors. Several groups have proven that the tumour 
growth is not inhibited by the powerful CD inhibitor pepstatine. These results exclude 
the importance of the CD enzymatic activity outside of the cell but as already 
mentioned pepstatine is unable to penetrate into the cell thus CD activation of growth 
factors inside the endosomes or the lysosomes is still a possibility. Different CPNP-
Pepstatine conjugates were synthesized and tested in vitro for their ability to inhibit 
MDA-MB-231 breast cancer cells growth. Some of these conjugates showed high 
cytotoxicity, probably via a Cathepsin D inhibition in the endosomes or the 
lysosomes. One of the most potent tested compounds was JMV4463. This 
compound was obtained by the conjugation of pepstatine with a CPNP as delivery 
system (AMPA4) and with solubilizing moiety composed of polyethylene glycol and D-
Arginine residue. The good in vitro results obtained with the vectorized pepstatine 
encouraged us to perform in vivo tests. We performed scale up synthesis of 
JMV4463 in order to obtain enough product for anti-cancer activity on mice in the 
near future.   
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RESUME 
 
Le passage des médicaments à travers la membrane cellulaire représente 
souvent une limitation majeur dans un grand nombre de thérapies (anti-cancéreuse, 
anti-virale par exemple). Des peptides vecteurs connus comme les CPPs (cell 
penetrating peptides) ont été utilisés avec succès pour introduire à l‘intérieur des 
cellules diverses molécules (protéines, peptides, siRNA, quantum dots) et présentent 
un fort potentiel dans l‘adressage de médicaments. Parmi les différents CPPs décrits 
dans la littérature la plupart sont des peptides basiques ou amphiphiles.  
 Nous nous sommes intéressés à l‘utilisation d‘oligomères non chargés 
construits à partir de motifs contraints mimes de dipeptides comme vecteurs de 
pénétration cellulaire. L‘internalisation cellulaire et leur localisation ont été établies à 
l‘aide de dérivés fluorescents par microscopie confocale. L‘étude de pénétration 
cellulaire par mesure de fluorescence a montré que des oligomères de (3S)-amino-5-
carbonylméthyl-2,3-dihydro-1,5-benzothiazépine-4(5H)-one] (DBT) sont aussi 
puissants que les oligomères d‘arginine (oligoArg), vecteurs de référence. Par 
microscopie confocale nous avons montré que ces composés sont internalisés dans 
les lysosomes. L‘efficacité d‘internalisation de nos composés a été confirmé par une 
méthode de quantification par spectrométrie de masse MALDI-TOF développée dans 
notre groupe. Cette méthode repose sur l‘utilisation conjointe d‘un marqueur UV-
absorbant dérivé de l‘acide α-cyano-4-hydoxycinnamique (HCCA) et d‘une matrice 
MALDI adaptée. Un effet important de discrimination spectrale est obtenu, 
permettant une amplification du signal de la molécule d‘intérêt dans un mélange 
complexe. Ainsi les faibles concentrations internalisées peuvent être détectées. 
Grace á cette technique et l‘utilisation d‘un étalon deutéré, nous avons caclulé la 
concentration intracellulaire de deux CPP de référence l‘octa-arginine et la 
pénétratine. Nous avons aussi étudier l‘internalization de petits oligomères construits 
à partir d‘acide 2-aminométhyl-phényl-acétique (AMPA). Par microscopie confocal 
nous avons constaté que ces petits oligomers sont internalisés par voie endo-
lysosomale.  
L‘efficacité de la pénétration cellulaire de ces petits oligomères aromatiques 
(oligoAMPA et oligoDBT) offre une nouvelle classe de vecteurs qui ont la particularité 
d‘être non-cationiques et hydrophobes. De tels composés pourraient être utilisés 
pour la délivrance de médicaments dans le traitment des maladies comme le cancer, 
les maladies lysosomales ou la maladie d‘Alzheimer.  
Afin de montrer que cette nouvelle classe de vecteurs est capable 
d‘internaliser des composés biologiquement actifs, nous les avons associé á un 
inhibiteur puissant de la Cathepsine D (CD) – la pepstatine. CD est une 
endopeptidase lysosomale qui dans des conditions normales est localisée dans les 
endosomes et les lysosomes. Pour cerains cancers, la CD est sur-exprimée et 
secrétée à l‘exterieur de la cellule. La CD est problement impliquée dans la 
prolifération des cellules cancéreuses par l‘activation de certains facteurs de 
croissances dans les endosomes. La pepstatine est une inhibiteur puissant de la CD. 
Cependant son efficacité thérapeutique potentielle est limitée par une faible capacité 
de pénétration des membranes cellulaires et une faible solubilité nécessitant de 
fortes doses pour l‘inactivation de la CD in vitro et in vivo. Afin d'améliorer son 
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efficacité et sa biodisponibilité, des conjugués de la pepstatine avec nos vecteurs de 
pénétration cellulaire, oligo (AMPA)4 et (DBT)4, et une partie solubilisante ont été 
développés. Certains de ces bioconjugués ont montré une toxicité élevée (IC50 = 
2.10-6) in vitro sur différentes lignées cellulaires tumorales. Des tests in vivo sur des 
souris sont prévus pour le futur. 
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I. INTRODUCTION 
 
My thesis work was performed in a close collaboration between the 
laboratories of ‗Institut des Biomolécules Max Mousseron UMR 5247 Université 
Montpellier 1- France‘ and the ‗Dipartimento delle Scienze Biologiche, C.I.R.Pe.B, 
Università Federico II di Napoli, Istituto di Biostrutture e Bioimmagini CNR‘ and the 
‗IRCM, Université Montpellier 1‘. The main research topics of my project were the 
fields of the foldamers and cell penetrating compounds. These two fields emerged 
about the same time two decades ago and are becoming increasingly important and 
studied in the beginning of this decade.  
I.1. Foldamers 
I.1.1. Foldamers structure 
In their attempt to mimic the natural folding of proteins, DNA and other natural 
molecules by smaller but yet stable non-natural oligomers, the researchers have 
developed the foldamers. Foldamers by definition are artificial oligomers with well-
defined structure (for extensive reviews see 4,13). Pioneer work in this field was set by 
the groups of Gellman14 and Seebach15 who used β-amino acids as templates for 
well-structured oligomers in solution and in crystalline solid state. The development in 
the field was highlighted by the review ‗Foldamers a Manifesto‘ by Gellman.16 During 
the last 15 years a lot of different foldamers have been constructed and 
characterized based on different frameworks that were oligomerized.4 The selection 
of the frameworks was often affected by the ease of the synthesis and the 
characterization of the oligomers. The interactions that define the secondary 
structure of the foldamers are similar to those of the proteins – H bonding, intrinsic 
conformational preference of the backbone, dispersion interactions, polar interactions 
and solvation. At the same time these unnatural oligomers are able to adopt 
organized structure for a lot shorter sequences than the natural proteins and 
peptides. Molecular modelling is often used to predict the possible conformations and 
most of the foldamers have been characterized by X-Ray crystallography, nuclear 
magnetic resonance (NMR) and circular dichroism investigations. Generally we can 
separate the foldamers in two categories depending on the presence or not of 
aromatic unit within the framework moiety: 
-Aliphatic frameworks - examples of this group include the β-peptides17, γ-
peptides18 and δ-peptides19, mixed α/β peptides20, oligoureas21, azapeptides22, 
pyrolinones23, α-aminoxy-peptides24 and peptoids25 (Figure I.1.1-1). Between these 
foldamers the β-peptides are the most extensively studied. The different frameworks 
gave rise to different well defined secondary structures like helices and beta-
sheets.17b  
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Figure I.1.1-1 Examples for aliphatic foldamers  
-Aromatic frameworks - the same factors that govern the folding of the 
aliphatic oligomers are important for the aromatic foldamers but in this case the π-π 
stacking and the geometric constraints are also crucial.4,26 For this type of molecules 
the non-covalent interactions that define the secondary structures are often more 
local compared to those of the aliphatic foldamers. Usually the interactions are 
between consecutive units, fact that makes them easier to predict. Notable examples 
in the field are the works of Huc group on quinoline27 and pyridin-derivated28 
oligoamides. Gong group have also designed and characterized oligoamide aromatic 
foldamers stabilized by a set of three-center intramolecular H-bonds.29 Hamilton and 
coworkers constructed foldamers based on terphenyl.30 Amblard and coworkers 
designed  foldamers composed of 2-aminomethyl-phenyl-acetic acid (AMPA) (Figure 
I.1.1-2).1  
 
Figure I.1.1-2 Examples for aromatic foldamers a) quinoline based foldamer27, b) oligoamide 
foldamer stabilized by three-center intramolecular H-bonds29, c) terphneyl foldamer30, d) 
foldamer constructed from 2-aminomethyl-phenyl-acetic acid1 (AMPA)  
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I.1.2. Foldamers function 
While the studies on foldamers were, at the beginning, more often driven by 
the understanding of the factors that govern their folding later, some foldamers were 
also developed with very interesting biological properties.4,13 The foldamers have 
many advantages over the natural peptides and the proteins. They are generally 
more stable to enzymatic degradation and they require fewer monomeric units to 
adopt an organized secondary structure, so they could be used as smaller more 
stable mimetics of the natural oligomers. This was very well illustrated by downsizing 
the natural host defense antimicrobial peptide Magainin31 from 2000-3000 Da to 
1000-2000 Da for the β-peptide analogues, 1000 Da for the arylamide antimicrobial 
foldamers32 and to around 500 Da for the phenylalkylnyl-based antimicrobial 
compound33 (Figure I.1.2).  
By virtue of their well-defined structure, the relationships between sequence 
and structure in the foldamers scaffolds are predictable. Therefore, they constitute 
privileged structures to distribute functional groups according to a specific three-
dimensional arrangement. Consequently they provide especially relevant tools for the 
design of miniature -helical mimetics able to block specific protein-protein 
interactions by mimeting protein-binding domains. In this field, Hamilton and 
coworkers constructed terphenyl backbone foldamer that mimics the distribution of 
side chains at positions i,i+4 and i+7 on one face of an α-helix.30 They used this 
template to successfully mimic the BH3 pro-apoptotic helix from Bak and to disrupt 
the Bak-Bcl-xL interaction.
34 In more recent studies the same group developed 
terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction.30 In a similar 
study Gellman et al. designed a chimeric α/β-peptide that binds to the Bcl-xL with an 
affinity of around 1nM that competes the tightest-binding BH3-derived α-peptides.35 
Later the same group reported a new more resistant to proteases α/β-peptide with 
similar activity obtained by sequence based design.36 In a recent work, they reported 
the co-crystallization of mixed α/β-peptide with the anti-apoptotic Bcl-xL.
37 These 
peptides could be used eventually as anti-cancer drugs because they could induce 
apoptosis in the cancer cells via their binding with the anti-apoptotic Bcl-xL.  
 
Figure I.1.2 a) Natural antimicrobial peptide magainin, b) β-peptide analogue of the 
magainin, c) arylamide analogue of the magainin, d) phenylalkylnyl-based analogue of the 
magainin. 
One of the very interesting applications of the foldamers is to use them as 
scaffolds for the synthesis of cell penetrating non-peptides or CPNP. As this point is 
of particular interest for our work, it will be discussed separately in the next chapter. 
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I.2  CPP – Cell Penetratin Peptides and CPNP – Cell 
Penetrating Non Peptides 
I.2.1 Cell Penetrating Peptides 
One of the major biological barriers for the drug delivery is the hydrophobic 
cell membrane. Only a few molecules that fit within a certain size range, polarity and 
charge are able to cross the cell membrane. At the same time a lot of potentially very 
powerful drugs like peptides, proteins and recently short interfering RNA (SiRNA) are 
unable to translocate the lipid bi-layer because of their size and charge. One of the 
possible ways to overcome this problem is to use the so called cell penetrating 
peptides or CPP. Since two decades ago, these ‗Trojan horse‘ molecules have 
emerged as promising tools for delivery of large set of cargos of different types and 
sizes (for recent reviews see5,3,38,39). One of the first examples for CPPs is the 
polycationic, arginine rich TAT peptide (TATp), derived from the 86-mer trans-
activating transcriptional activator (TAT) protein encoded by human 
immunodeficiency virus type 1 (HIV-1).40 TATp sequence is YGRKKRRQRRR. In 
another pioneer work, Prochiantz and coworkers have discovered the amphipathic 
penetratin derived from the homeodomain of Drosophila Antennapedia.41 Penetratin 
sequence is RQIKIWFQNRRMKWKK. The oligoarginines Arg8 or Arg9 derived from 
the polycationic TAT peptide were discovered by the groups of Wender and Futaki.7,6 
These synthetic peptides exhibited often a better uptake than TATp and penetratine. 
All these CPP were cationic and/or amphipathic peptides. The internalization 
pathway or combination of pathways for the CPP is very controversial and results 
vary from one study to another. The interaction with the charged anionic molecules of 
the cellular membrane seems to be very important.42 Divalent hydrogen binding 
between the guanidino moiety of the arginine and the phosphates, sulphates and 
carboxylates (Figure I.2.1-1) is reported as one of the driving forces of the 
internalization. Indeed, binding of these permeating peptides to cell surface 
proteoglycans could promote the interaction of the CPPs with the cellular 
membranes, facilitating the subsequent interactions necessary for the translocation 
process; in an alternative scenario, this same binding step could induce by itself 
certain endocytotic mechanisms, leading to CPP internalization.  
 
Figure I.2.1-1 Strong divalent hydrogen bonds could be formed by side-chain guanidino 
moiety of arginine with phosphates, sulfates, and carboxylates of the cell membrane 
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Different paths of internalization have been observed depending on the type of 
CPP, their concentration, the type of the cell line, the cargo attached to the CPP, and 
even the counter ion of the cationic residues.38 The major pathways seem to be 
either energy dependent endocytosis or energy independent direct internalization. 
The possible endocytotic pathways reported in the literature are the caveola 
mediated endocytosis, macropinocytosis and clathrin-mediated endocytosis.3 The 
proposed mechanisms for direct translocation are the torodial pore, barrel stave pore, 
inverted micelle and carpet model.3 The internalization pathway for most of the CPP 
seems to be a combination of two or more of these mechanisms. For example the 
oligoarginine is reported to penetrate cells at 4°C and at 37°C which suggests a 
mixture between energy dependent and energy independent internalizations.43 CPPs 
conjugated to small cargos seem more able to penetrate via the direct internalization 
mechanisms while big cargos are internalized mainly via endocytosis. Generally 
there are two approaches for the internalization of drugs by CPP/CPNP (Figure I.2.1-
2): 
- The covalent strategy in which the drug is covalently linked to the CPP. Following 
this strategy have been internalized small molecules44, peptides and proteins45, PNA 
and PMO39, imaging agents46 and so on. 
 
 
 
 
 
 
 
 
Figure  I.2.1-2 Strategies for internalization of drugs by CPP/CPNP 
 
- The non-covalent strategy in which the usually anionic drug (SiRNA or DNA) is 
complexed by the cationic CPP.5 Cholesterol coupled to polyarginine47, the chimeric 
peptide MPG48 and many others have been successfully used for the internalization 
of SiRNA or DNA. This strategy is also applied for the internalization of 
nanoparticles.5 A small dogma in the field is that all CPPs are charged cationic 
compounds. In fact hydrophobic segments from protein signal sequences or 
membrane translocating sequences (MTS)49, as well as non-charged polyproline50 
peptides were described as effective cell membrane transporters. Recently Futaki et 
al.51 reported a small hydrophobic sequence PFVYLI that successfully translocated 
cargos across the cell membrane. While most of the work in the field is directed to 
charged poly-cationic peptides we should note that for the internalization of CPP or 
CPNP an interaction with the cell membrane is crucial. While this interaction is often 
electrostatic at first, we should not exclude the possibility of hydrophobic interactions 
with the lipid rafts or other parts of the membrane to induce internalization. Some 
toxicity effects are linked to the administration of high doses of poly-cationic 
 
 
Endocytosis/ 
Direct translocation 
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compounds52 thus the development of non-charged vectors is of considerable 
interest.  
 I.2.2 Cell Penetrating Non-Peptides 
As we previously described, foldamers are very interesting framework for 
CPNP because of their small size, resistance to protease degradation and well 
defined structure. Seebach and coworkers performed experiment with polycationic β-
peptides53 and obtained similar results to those of polycationic α-peptides but with 
compounds that were resistant to enzyme degradation. Wender and coworkers 
reported a polycationic peptoid54 and recently an oligocarbonate molecular 
transporter55 obtained by ring opening oligomerization. Chmielewski and coworkers56 
described hydroxyproline oligomers bearing precisely arrayed hydrophobic and 
cationic appendages that were internalized in some cases 35 times better than the 
TATp. The principal drawback of these molecules is their difficult synthesis. Gellman 
and coworkers designed amphipathic β-peptides that internalized into cells at 
concentration of 8 μM.57 Further studies revealed an endocytotic pathway of 
internalization.  
Recently some CPNPs that differ significantly from peptides were developed. 
Huc group designed aromatic amide foldamers functionalized with peripheral cationic 
side chains that delivered FITC to HeLa cells58 with an efficiency similar to TATp. In 
one of the most interesting studies to date, Selwood and coworkers59 reported the so 
called SMoC (small molecule carrier) (Figure I.2.2-1). This compound is comprised of 
a biphenyl core functionalized with 4 guanidinium groups in an arrangement that 
mimics the display of side chains of an α-helix. SMoC was able to mediate dyes and 
recombinant proteins into a variety of cell lines with efficiency similar to that of TATp. 
By using 4G-SMoC the 23.5 kDa DNA replication suppressor gaminin was 
successfully delivered to human fibroblast. 4G-SMoC-gaminin effectively suppressed 
DNA synthesis in NIH-3T3, WI-38 HDF, HeLa S3 adenocarcinoma cells, and MOLT-4 
leukemic lymphoblasts in vitro. One should note that this powerful CPNP is only 
about 600 Da making it one of the smallest known cell penetrating compounds. The 
high density of the guanidinium charges and the hydrophobicity of the two phenyl 
rings seem very important for its internalization. 
 
Figure I.2.2-1 SMoC vector 
As in the case of the CPP, not all CPNP are charged compounds. While 
studding the enzymology and biochemistry of the protein palmitoylation Stefan et al. 
discovered a small cell penetrating non-charged lypo-peptide60 (Figure I.2.2-2) that 
was internalized by Jurkat lymphocytes. In a very elegant study Simons and 
coworkers have vectorized a potent transition state inhibitor of the β-secretase 
cleavage of β-amyloid precursor protein and thus stopped the β-amyloid peptide 
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production.61 The inhibitor was inactive in vitro because of its inability to reach the 
endosomes where the β-secretase enzyme is the most effective. To confront this 
problem the authors have linked the inhibitor to a sterol moiety (Figure I.2.2-2) via a 
polyethylene glycol linker. This bioconjugate was internalized and localized in the 
endosomes supposedly via an interaction with the lipid rafts and subsequent 
endocytosis. The sterol linked inhibitor was able to inhibit the -secretase enzyme 
activity at very low concentration of 200 nM in vitro and also increased the survival 
rate of triple transgenic Drosophila expressing human wild type β-amyloid peptide. 
 
Figure I.2.2-2 Different non-charged CPNP 
I.2.3 Determination of the intracellular concentration of CPP/CPNP  
Different methods for detection of CPP and CPNP inside the cell have been 
developed each of them with its distinctive advantages and drawbacks. As none of 
these methods is perfect the development of new ones is of considerable scientific 
interest.   
Total fluorescence emission measurement (TFEM) 
In this experiment cells are first incubated with fluorescently labelled 
compound for a certain time (Figure I.2.3-1). A first washing is performed to take 
away the residual non-internalized compound.  
 
Figure I.2.3-1 Basics of total fluorescence emission measurement 
After that, a trypsin treatment is performed  in order to digest the cell membrane-
adsorbed cell-penetrating compounds.62 After this treatment, cell lysis is performed. 
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The obtained media is irradiated with UV light. Then estimation of the internalized 
compound could be made by detection of the UV emission of the fluorescent tag. The 
drawback of this technique is that it is relevant only when CPPs are compared to 
another one in the same experimental conditions because no accurate estimation of 
the intracellular concentration could be made. Another problem is the fact that some 
times CPPs or CPNPs are not effectively removed by the washing steps thus some 
residual fluorescence from non-internalized compounds is detected.  
Fluorescence-activated cell sorting 
One of the standard procedures for detection of a fluorescently labelled CPP 
and CPNP inside the cells is the fluorescence-activated cell sorting or FACS. FACS 
is a specialized type of flow cytometry that provides a method for sorting a 
heterogeneous mixture of biological cells into two or more containers, one cell at a 
time, based upon the specific light scattering and fluorescent characteristics of each 
cell.63 It is a useful scientific instrument, as it provides fast, objective and quantitative 
recording of fluorescent signals from individual cells as well as physical separation of 
cells of particular interest. The advantage of FACS is that it allows separating 
different population of cells depending on the quantity of internalized fluorescently 
labelled compound. This methodology has the same disadvantages as the total 
fluorescence measurement. 
Confocal microscopy  
Confocal microscopy is an optical imaging technique used to increase optical 
resolution and contrast of a micrograph by using point illumination and a spatial 
pinhole to eliminate out-of-focus light in specimens that are thicker than the focal 
plane.64 Plane images of cells incubated with fluorescently labelled compounds could 
be obtained by this technique. Prior to internalization experiment, cells could be 
incubated with markers for different organelles so that the exact localization of 
CPP/CPNP inside the cell could later be determined (Figure I.2.3-2).  
 
 
 
 
 
Figure I.2.3-2 Examples of confocal images of cells incubated with markers for: A) the cell 
membrane (red) and nucleus (blue) B) the lysosomes (red). 
This technique is very useful in a combination with the previous two mentioned 
(FACS and TFEM) because it could answer the question if the compound is really 
internalized inside the cell or just attached to the membrane. However, as the 
previously described techniques, it cannot give an accurate quantification of the 
internalized compound. 
 
 
A B 
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MALDI TOF MS techniques for the accurate calculation of the intracellular 
concentration of CPP or CPNP  
All the previously mentioned methods for detection are unable to give an 
accurate calculation of the intracellular concentration of CPP/CPNP. To resolve this 
problem Burlina and al. have developed a highly reproducible quantification method 
based on MALDI-TOF mass spectrometry.10 In this method cells are incubated with 
biotin-labelled CPP in a similar way as in the case of the TFEM. After washing steps 
a cell lysis is performed and the biotin-labelled CPPs are captured by streptavidin 
coated beads. The beads are washed and a known amount of deuterated biotin 
labelled CPP (D-CPP) is added. After that the beads are analyzed by MALDI-TOF 
MS. The peaks of the [M+H]+ deuterated and non-deuterated CPP are integrated and 
by their ratio the intracellular concentration could be determined with very good 
precision. 
The step of biotin-labelled CPP capture from streptavidin is critical for the 
accuracy of the quantification. Indeed the lysate could contain molecules that may 
hamper the CPP capture by the streptavidin coated beads. The development of a 
similar method but devoid of any separation procedure is of considerable practical 
interest. 
I.2.4 CPP/CPNP-Drug bioconjugate intracellular localization  
As we have already discussed a lot of effort has been put in the design of 
potent CPP or CPNP vectors. Even more important than the intracellular 
concentration of the vector is its compartmentalization inside the cell. Anti-cancer 
drugs should often be delivered to the cytosol or the nucleus.44 SiRNA should be 
delivered to the RISC apparatus in the cytosol65, DNA strands to the nucleus. For a 
lot of these drugs, once internalized endosomal escape is very important thus 
different techniques have been developed to avoid the endosomal entrapment. 
Nuclear and cytosol localization sequences have been designed to help the drug 
reach its specific destination.48 
At the same time very interesting targets are located in the endosomes as the 
already mentioned -secretase enzyme responsible for the Alzheimer‘s disease.61 
Another target inside the endosomes of the cancer cells is the Cathepsin D enzyme. 
As this enzyme was a prime target for our group we will discuss its implication in 
cancer development in more detail in the next chapter. 
I.3 Cathepsin D 
Cathepsin D (CD) is a soluble lysosomal aspartic endopeptidase synthesized 
in rough endoplasmic reticulum as preprocathepsin D (pCD).12 pCD is a glycoprotein 
with two N-linked oligosaccharides (mannose-6-phosphate lysosomal localization 
signals) that is targeted to the intracellular vesicular structures (lysosomes, 
endosomes, phagosomes) 
Upon entering the acidic endosomal and lysosomal compartments proteolytic 
cleavages of the pCD result in the formation of the active enzymatic form CD. Under 
normal physiological conditions pCD is sorted to the lysosomes and found 
intracellularly but in some pathological and physiological conditions like cancer 
pCD/CD escape the normal targeting mechanism and is secreted from the cell. Once 
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secreted to the outside pCD can be endocytosed via M6PR or yet unknown receptor 
by both cancer cells and fibroblasts. Once endocytosed, pCD undergoes maturation 
into the enzymatically active CD. CD has been studied mainly for its implication in 
cancer development and is subjected as an independent tumor marker.  
I.3.1 Cathepsin D and Cancer 
Numerous studies clearly demonstrate that pCD secreted from cancer cells 
serve as an autocrine factor for cell growth of breast cancer and other types of 
cancer such as lung cancer.12 Breast cancer cells with down-regulated expression of 
pCD by antisense gene transfer displayed reduced growth in vivo and in vitro.66 
Similar results were obtained after incubation with pCD anti-bodies.67 The exact 
implication of CD on the cancer growth is much debated and is still an object of 
study. There are two predominant theories for the CD action on cancer proliferation. 
One is that the effect is dependent on the enzymatic activity of the CD and the other 
one is that the mitogenic activity is independent of the enzymatic activity. The exact 
mechanism of action of the over-expressed CD in cancer cells is probably a 
combination of both. 
Cathepsin D enzymatic related effect on mitogenic activity 
An enzymatic activity of CD could be responsible for the activation of several 
growth factors and growth factor receptors.68 Moreover it is possible that CD is 
responsible for the degradation of the extracellular matrix. CD digests various 
chemokines and may thus attenuate anti-tumor immune response. Several groups 
have proven that the tumor growth is not inhibited by the powerful CD inhibitor 
pepstatine A (Figure I.3.1).69 
 
Figure I.3.1.Pepstatine A – an 7 nM inhibitor of the Cathepsin D.70 Pepstatine is unable to 
cross the cell membrane and is ineffective in vitro or in vivo. Statine crucial residues for 
inhibitory activity are shown in blue. 
Pepstatine while a very potent transition state inhibitor of the CD (IC50 = 7nM) has a 
low ability to cross the cellular membrane.70 Moreover pepstatine activity in vitro or in 
vivo is hampered by its poor solubility in water. So if we could exclude the importance 
of the CD enzymatic activity outside of the cell a specific activation of growth factors 
inside the endosomes is still a possibility. Synthesis of pepstatine conjugated to CPP 
or CPNP for better internalization is of considerable interest because it allows us to 
study the importance of CD inhibition inside the cell and its implication on cancer 
growth. The CPP or CPNP used for this experiment should deliver the cargo 
preferably to the endosomes and lysosomes where the CD enzymatic activity is the 
most important. A pepstatine-CPP or pepstatine-CPNP conjugate could be an 
interesting anti-breast cancer drug candidate.  
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Pro Cathepsin D non-enzymatic related mitogenic activity 
Some studies have shown that the treatment of cancer cell with enzymatically 
inactive pCD mutant has the same effect as the treatment with the wild type CD. This 
research suggests that a non-enzymatic effect of the pCD might also be important for 
the cell proliferation.71 The exact mechanism of the pCD mitogenic effect remains 
unclear. Some scientific groups have shown that pCD binds to the surface of breast 
cancer cells.71 Thus an interaction with an unknown cell receptor with signalling 
properties could be responsible for the increased cells proliferation. 
I.3.2 Assay for CD enzyme activity 
To measure CD enzymatic activity we used protocol reported by Erikson and 
coworkers.72 They used fluorogenic peptide substrate of CD which contains 
fluorophore and quencher groups in the same molecule. The fluorescent signal in the 
uncleaved substrate is quenched due to resonance energy transfer between the 
fluorophore and the quencher groups. In this case EDANS (5-[(2-
aminoethyl)amino]naphthalene-1-sulfonic acid) and DABCYL (4-(4-
dimethylaminophenylazo) benzoic acid) were respectively the fluorophore and the 
quencher (Figure I.3.2).  
 
Figure I.3.2 Test for enzymatic activity of the CD based on fluorogenic peptide substrate 
This donor-acceptor pair is characterized by a number of advantages such as the 
extremely good spectral overlap of EDANS emission with the strong absorption band 
of DABCYL, good quantum yield, stability against photobleaching and Stokes shift of 
over 100 nm for EDANS. Here we used the quenched fluorescent synthetic peptide 
substrate EDANS–CO–CH2–CH2–CO–Arg-pro-Ile-Phe-Phe-Arg-leu-Gln–DABCYL–
OH with a cleavage site of Phe-Phe, previously described by Baechle and 
collaborators to be specific of  CD.73 When CD is activated the cleavage site of Phe-
Phe is degraded, the fluorescent probe is free from the quencher and thus 
fluorescence is emitted. On the opposite when CD is inhibited there is no cleavage of 
the fluorogenic peptide substrate and thus no fluorescence emission. By this method 
the residual activity of the CD after incubation with an inhibitor at certain 
concentration could be measured.  
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II. PROJECT AIMS 
 
As a part of a program for foldamer design, oligomers composed from different 
β-turn mimetics were constructed in-silico and tested by molecular dynamics for their 
ability to adopt organized structure.1 Among the different motifs selected by this 
program, two dipeptide mimetics, (3S)-amino-5-(carbonylmethyl)-2,3-dihydro-1,5-
benzothiazepin-4(5H)-one or DBT2 and 2-aminomethyl-phenyl-acetic acid or AMPA1 
(Figure II.1), were selected as frameworks for their suitability to adopt helical 
structure. Our first task was to develop a highly efficient scale up synthesis of these 
two moieties protected by Fmoc group onto their amino function. Next these Fmoc 
protected unnatural aminoacids were used to construct, via standard solid phase 
peptide synthesis (SPPS), oligomers of different lengths and modifications introduced 
at their N-terminus. We planned to study the structure of these oligomers by NMR, 
circular dichroism and X-Ray crystallography. Such organized oligomers could be 
used for inhibition of protein-protein interactions or as frameworks for antibiotics and 
CPNP. 
 
 
Figure II.1. (3S)-amino-5-(carboxylmethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one or 
DBT and  2-aminomethyl-phenyl-acetic acid or AMPA structures 
 
In a parallel study we hypothesized that short oligomers constructed by DBT or 
AMPA moieties could translocate the cellular membrane and be used as a new class 
of CPNP (see section I.2.2). Oligomers from different size were synthesized and 
marked by a fluorescent dye. Our discovery that AMPA tetramers and especially DBT 
tetramers are potent CPNP that are able to transport fluorescent dyes with high 
efficiency encouraged us to further investigate their biological activities and set new 
aims to my thesis. First we planned to straightforward evaluate the concentration of 
the CPNP internalized inside the cells by developing a new general methodology 
based on MALDI-TOF mass spectrometry (MS) which does not require any 
purification or separation steps.    
In order to study an eventual interaction of the benzothiazepine oligomers with 
a specific receptor and then better understand the internalization mechanism of our 
CPNP, compounds like the fluorescein labelled LBT tetramer with inversed chiral 
configuration were synthesized. 
Another direction for research was to synthesize bioconjugates between our 
newly discovered CPNP and some biologically active compounds that are unable to 
cross the cell membrane on their own. We planned to vectorize pepstatine - a 
powerful inhibitor of the Cathepsin D (see section I.3.1). Pepstatine while a potent 
transition state inhibitor of the CD is hindered in vitro or in vivo by its poor solubility in 
water and its inability to cross the cell membrane. Our aim was to improve pepstatine 
bioavailability by connecting it to a CPNP and solubilizing moieties. These 
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bioconjugates were tested for their ability to inhibit CD and cancer cells growth. By 
doing this we should be able to: 
-prove that our set of CPNP is able to traffic biologically relevant cargos   
-evaluate the effect of CD inhibition inside the endosomes and the lysosomes on the 
cancer cell proliferation 
-discover a new target for breast anticancer therapy 
Different CPNP-Pepstatine conjugates were synthesized and tested for cell 
toxicity on MDA-MB-231 breast cancer cells in vitro. Some of the AMPA oligomers 
conjugated to pepstatine showed high toxicity which encouraged us to perform tests 
in vivo on mice with one of our best compound (JMV4463). For that purpose, 
important quantities (about 100 mg) of compound JMV4463 were synthesized.  
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III. RESULTS AND DISCUSSION 
 
III.1 Synthesis of Fmoc-DBT-OH and Fmoc-AMPA-OH 
As mentioned in the project aims we needed the (3S)-amino-5-
(carboxylmethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (DBT) and 2-
aminomethyl-phenyl-acetic acid (AMPA) moieties protected by the Fmoc group in 
order to use them later for standard SPPS. We synthesized the Fmoc-DBT-OH via 7 
steps liquid phase synthesis (Figure III.1 and Materials and Methods) starting from 
125 mM of H-D-Cys-OH.HCl (Materials and methods). We obtained about 62.5 mM 
(29 gr) of Fmoc-DBT-OH corresponding to a global yield of around 50%. More than 
100 grams of Fmoc-DBT-OH were synthesized during the course of my PhD thesis 
fallowing this efficient strategy. With the obtained quantity we were able to synthesize 
an important number of DBT oligomers for structural and biological studies. 
 
Figure III.1 Synthesis of Fmoc protected (3S)-amino-5-(carboxylmethyl)-2,3-dihydro-1,5-
benzothiazepin-4(5H)-one or Fmoc-DBT-OH 
The Fmoc-LBT-OH monomer with inversed chiral configuration of the amino-
group  was synthesized following the same methodology but starting from H-L-Cys-
OH.  AMPA was purchased by commercial supplier and protected with Fmoc group 
by Fmoc-OSu in the same reaction conditions as for the DBT (see Materials and 
Methods) 
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III.2 Structural studies of DBT and AMPA oligomers 
III.2.1 Syntesis of DBT and AMPA oligomers for structural studies 
Synthesis of linear oligomers  
The secondary structure determination of the DBT and AMPA oligomers was 
one of the principal aims of my thesis. This important task should help the 
construction of biomimetics with correctly positioned crucial functions on a target-by-
target basis. In order to do this we synthesized via standard SPPS on Ring amide 
(RA) polystyrene (PS) resin using HBTU/DIEA as a coupling reagent, AMPA and 
DBT oligomers of different lengths and we capped them at the N-terminus with acetyl 
group or Z(Br) (2-bromobenzyl oxycarbonyl). The heavy Br atom is supposed to give 
a better resolution of the X-Ray structure if a compound is crystallized. At the end the 
compounds were cleaved from the resin by TFA and purified by preparative HPLC 
chromatography (see Materials and Methods). The synthesis of the oligomers is 
summarized on Figure III.2.1-1 
III.2.1-1 General SPPS synthesis of DBT, LBT and AMPA oligomers capped by Z(Br) or 
acetyl group at the N-terminus for crystallization and NMR structural studies respectively. 
The AMPA and DBT oligomers synthesized by this method are summarized in Table 
III.2.1-1 
Table III.2.1-1 Linear oligomers synthesized for structural studies 
Compounds Type of structural tests 
Ac-(DBT)n-NH2  n=[1-8] NMR studies and Crystallization essays 
Z(Br)-(DBT)n-NH2 n=[4-5] Crystallization essays 
Ac-DBT-LBT-DBT-LBT-NH2 NMR studies and Crystallization essays 
Ac-(AMPA)n-NH2  n=[4-5] NMR studies and Crystallization essays 
 
Synthesis of cyclic oligomers  
Cyclic foldamers are interesting scaffolds for CPNPs, antibiotics and 
nanostructures. Linear DBT hetero and homo-oligomers were synthesized by SPPS 
and subsequently cyclized in solution. The first DBT moiety was anchored to the 2-
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chlorotrityl PS resin in the presence of DIEA. After that DBT homo-oligomers and 
[Lys(Boc)–DBT]n hetero-oligomers were synthesized via standard SPPS by 
HBTU/DIEA activation (Figure III.2.1-2). The hetero-oligomers were cleaved from the 
resin by a solution of TFE/DCM 3/7 v/v in order to keep the Boc protection of the 
lysine residue side chain. The cyclization steps were performed by BOP/NaHCO3 
activation in DMF at low concentration of the oligomers (200 μM) in order to avoid 
dimerization. After cyclization, a treatment with a solution of 99% TFA was performed 
and the cyclic compounds were purified by HPLC preparative chromatography. In the 
case of DBT homo-oligomers the compounds were cleaved directly by TFA 99% and 
cyclized via BOP activation in the presence of NaHCO3 as base in DMF at 
concentration of 200μM. After cyclization the compounds were purified by HPLC 
preparative chromatography. 
 
Figure III.2.1-2 General synthesis of -(Lys-DBT)n- cyclic hetero-oligomers. The same 
strategy was applied for the synthesis of the -(DBT)n- cyclic homo-oligomers but they were 
directly cleaved from the resin by TFA 99% and then cyclized by BOP activation in DMF.   
The cyclic hetero and homo-oligomers obtained following this strategy are 
summarized in Table III.2.1-2. We were unable to obtain the cyclic compound               
-(DBT)2-. During the attempt for cyclization of H-(DBT)2-OH only dimerization of this 
compound was obtained even at 200 μM concentration. This dimer is probably too 
constrained to cyclize.  
Table III.2.1-2 Cyclic oligomers synthesized for structural studies 
Compounds Type of structural tests 
-(DBT)3- NMR studies and Crystallization essays 
-(DBT)4- NMR studies and Crystallization essays 
-(Lys-DBT)3- NMR studies and Crystallization essays 
-(Lys-DBT)4- NMR studies and Crystallization essays 
 
III.2.2 Crystallization assays  
Crystallization essays were performed with the compounds reported in section 
III.2.1 in order to obtain crystals suitable for X-Ray structural studies. The choice of 
the solvent for these experiments was motivated by the compounds solubility. For 
example the longer DBT linear and cyclic oligomers were soluble only in DMSO. The 
compounds and the solvents used for crystallization essays are reported in Table 
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III.2.2. Small crystals were obtained from Ac-(DBT) 6-NH2 in DMSO but their size was 
not important enough for X-Ray crystallography studies. Powder diffraction 
experiments are currently performed with compounds: -(Lys-DBT)3-, -(DBT)3- and  
Ac-(DBT) 6-NH2. 
 
Table III.2.2 Compounds and solvents used for the crystallization assays  
Compound Crystallization essay solvent 
Ac-(DBT)n-NH2 n=[1-4] DCM, DMSO, TFE, CH3CN 
Ac-(DBT)n-NH2 n=[5-8] DMSO, DCM 
Ac-(AMPA)n-NH2 n=[4-5] DMSO, DCM 
Z(Br)-(DBT)n-NH2; n=[4-5] DMSO 
-(DBT)n-; n=[3,4] DMSO 
-(Lys-DBT)n-; n=[3,4] EtOH 
 
III.2.3 NMR structural studies of linear DBT oligomers 
 Our main effort for structural characterization by NMR was concentrated on 
the series of compounds Ac-(DBT)n-NH2 with n=[1-8] as we had no data about their 
secondary structures. Cyclic homo and hetero-oligomers were also studied but their 
symmetrical structures gave rise to too much signals overlays.  
III.2.3.1 Choice of deuterated solvent 
Our first task was to choose deuterated solvent for the NMR structural studies 
of the DBT oligmers. Most of these compounds were insoluble in pure water, TFE, 
MeOH or EtOH, thus we excluded these solvents. This narrowed our choice to CDCl3 
and DMSO. Figure III.2.3.1 shows the 1H NMR spectra of Ac-(DBT)4-NH2 obtained in 
d6-DMSO or in CDCl3. The peaks of the protons in the spectrum obtained in DMSO 
are a lot better defined and resolved than the broad peaks obtained in CDCl3. These 
results could be explained by the existence of several conformers in intermediate 
chemical exchange in CDCl3. The sharp resonances in d6-DMSO suggested a single 
well defined conformation or fast exchange between two or more conformers. 2D [1H, 
1H] NOESY experiments were performed with compound JMV4169 in d6-DMSO and 
in CDCl3 at 0.5 mM concentration. Practically no NOE signals were observed in the 
CDCl3 solvent, whereas the spectrum obtained in d6-DMSO showed several proton-
proton interactions that could suggest more defined organization of the oligomer in 
this solvent (Figure III.2.3.3-4 A). Possible explanation is that the structure of 
JMV4169 in DMSO is promoted by solvophobic interactions that are more 
pronounced in the case of a polar solvent. Moreover, DMSO was a better choice for 
the structural studies also because it is more similar to water due to its polarity and 
ability to form hydrogen bonds.  
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Figure III.2.3.1 1H NMR of Ac-(DBT)4-NH2 obtained in d6-DMSO or CDCl3 at 2   C.  
III.2.3.2 ‘NOE walk’ and assignment of the protons 
Compounds Ac-(DBT)n-NH2 with n=[1-8] were extensively studied in d6-DMSO 
by 1D 1H, 2D [1H, 1H] NOESY, 2D [1H, 1H] ROESY, 2D [1H, 1H] TOCSY and 2D [1H, 
1H] COSY NMR experiments. The spectra were analysed by the CARA 1.5.5 
software. The atom nomenclature we chose for the DBT moiety follow that commonly 
used for amino acids and is summarized on Figure III.2.3.2-1 
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Figure III.2.3.2-1 Nomenclature used for the DBT moiety. Atom names are followed by 
DBT:BX where X corresponds to the number of the residue in the sequence (N-terminal 
residue being the first one and the C-terminal being the last one). For example the HA atom 
of the C terminal residue in the case of Ac-(DBT)4-NH2 is noted HA DBT:B4 and HA of the N 
terminal residue is assigned HA DBT:B1 
Figure III.2.3.2-2 shows the so called ‗NOE walk‘ we performed to assign the 
chemical shifts of the protons of the Ac-(DBT)3-NH2 oligomer starting from the C- and 
N-terminus of the molecule. Starting from the N-terminus we determined H DBT:B1 
by its interaction with the acetyl group protons. Then we identified HA DBT:B1 by its 
cross peak with H DBT:B1. HB2 and HB3 DBT:B1 were determined by their 
interaction with HA DBT:B1. HE2 DBT:B1 was assigned by its intense interaction 
with HB2,3 DBT1. We were then able to assign the aromatic protons of the first 
residue using interactions detected by 2D COSY and 2D TOCSY NMR experiments. 
Through the aromatic HE1 DBT:B1 we were able to indentify HD2,3 DBT:B1. Then 
through interactions with HE1 DBT:B1 and HD2,3 DBT:B1 we were able to determine 
H DBT:B2. Once H DBT:B2 assigned the same algorithm was used to determine the 
protons of the second and third residue.  
  
Figure III.2.3.2-2 ‘NOE walk’ for the assignment of the atoms of the Ac-(DBT)3-NH2 oligomer 
starting from the C- and N- terminal residues (Blue and red arrows). The same strategy was 
used for the assignment of the protons of the oligmers Ac-(DBT)n-NH2 n=[1-6]. In the case of 
the Ac-(DBT)n-NH2 n=7,8 was observed too much overlay of the proton signals for the 
accurate assignment.  
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Alternatively the NOE walk could start from the C-terminus where HD2,3 
DBT:B3 could be determined by their cross peak with the amide protons. HE1 
DBT:B3 was identified by its interaction with HD2,3 DBT:B3. Then by TOCSY and 
COSY spectra we assigned the aromatic protons of the 3th DBT residue and most 
importantly HE2 DBT:B3. We determined HB2,3 DBT:B3 by its cross peak with HE2 
DBT:B3. HA DBT:B3 and H DBT:B3 could then easily be assigned. Next step was to 
determine HD2,3 of the second residue by their interactions with H DBT:B3. The 
same algorithm was then used to assign the protons of the second and first residues. 
Using similar ‗NOE walks‘ we were able to assign all the protons of the oligomers Ac-
(DBT)n-NH2 n=[1-6] (Materials and Methods Section V.7.1) . In the case of the Ac-
(DBT)n-NH2 n=7,8 was observed too much overlay of the proton signals for accurate 
assignment. 
III.2.3.3 Measurement of NOE and ROE volumes and determination of distance 
restrictions in the oligomers 
Study of Ac-(DBT)n-NH2 with n=[1-4] by 2D ROESY experiment 
First we concentrated our effort on the series of compounds Ac-(DBT)n-NH2 
with n=[1-4] because in their spectra was observed a lot less overlay compared to the 
longer oligomers. The comparison between the ROESY and NOESY experiments 
showed more cross-peaks in the ROESY spectrum, especially between the aliphatic 
HD2,3 protons and the aromatic protons (see Figure III.2.3.3-1 for the ROESY 
spectrum of Ac-(DBT)4-NH2 and Figure III.2.3.3-4 A for the NOESY spectrum). These 
findings could be explained by the fact that ROESY spectra are more adapted for the 
analysis of small or medium sized molecules. Indeed this kind of molecules has 
correlation times which lead to very small or zero NOEs on high-field spectrometer, 
where the correlation time is a function of the molecular shape and size. Thus we 
decided to examine first the ROESY spectra.  
 
Figure III.2.3.3-1 ROESY spectrum (MT=250ms) of Ac-(DBT)4-NH2. 
HD2,3/Aromatic 
interactions 
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Figure III.2.3.3-2 sums up some of the characteristic ROEs we observed in Ac-
(DBT)4-NH2. In order to obtain distance restrictions, we carried out manual integration 
of the volumes of the ROEs by means of NEASY, a tool of CARA software. We used 
the volume of the interaction between the vicinal HD2 and HD3 atoms in the DBT:B1 
residue as reference to transform these volumes into distances. 
 
Figure III.2.3.3-2 ROEs observed in the ROESY (MT=250ms) spectrum of Ac-(DBT)4-NH2. 
The distance between HD2,3 and HE1 was estimated around 4 Å equal to the distance 
between HD2,3 and HE2. These interactions were ruled by us as artefacts. 
During the preliminary analysis of these data we observed that the distances 
between HD2,3-HE1 and HD2,3-HE2 in the same residue were very similar (in the 
range of 4 Å). Unfortunately there is no possible conformation of the DBT moiety that 
respect these distance restrictions. In fact there is no possible structure in which HE2 
is closer than 5 Å to HD2,3. Thus we had to judge these ROE interactions as 
artefacts. In fact ROESY is probably the most artefact-ridden one of all 2D methods. 
TOCSY-ROE combinations are particularly tricky, because they have the same 
phase as true ROEs. A TOCSY transfer between strongly coupled protons like HE1 
and HE2, in combination with a ROE between HD2,3 and HE1 could give a false 
ROESY peak between HD2,3 and HE2 (Figure III.2.3.3-3). Such artefacts could 
seriously hamper the calculation of the exact distances inside the molecule or even 
give interactions that do not exist at all. Thus we could not use the distance 
constraints obtained from ROESY spectra for the structure determination of 
compounds Ac-(DBT)n-NH2 with n=[1-4]. Such artefacts are less common for the 
NOESY sequence. This fact pushed us to look deeper into the NOESY spectra. 
 
Figure III.2.3.3-3 Mechanism for the detection of false ROEs in case of protons with very 
strong TOCSY coupling. 
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Structural studies of Ac-(DBT)6-NH2 by the 2D NOESY experiment 
As we already mentioned, NOESY spectra of compounds Ac-(DBT)n-NH2 
n=[1-4] showed few NOE interactions, as expected for such small molecules (Figure 
III.2.3.3-4 A). We examined higher DBT oligomers – Ac-(DBT)n-NH2 n=[5-8] by 2D 
NOESY experiments. Spectrum of compound Ac-(DBT)5-NH2 and especially 
spectrum of compound Ac-(DBT)6-NH2 showed numerous NOEs that strongly 
suggested a well defined secondary structures of these compounds. Spectra of 
compounds Ac-(DBT)n-NH2 n=7,8 exhibited similar patterns but also a lot of overlay 
so correct assignment of the protons was difficult. Figure III.2.3.3-4 is a comparison 
between the NOESY spectra of the Ac-(DBT)4-NH2 and Ac-(DBT)5-NH2. On the 
tetramer spectrum were observed few intra-residual NOEs between the aliphatic 
protons with the aromatic protons and the aromatic with the amide protons (Figure 
III.2.3.3-4 A). For the pentamer we identified numerous inter and intra-residue 
interactions between the amide protons and the aromatic protons, aliphatic-aliphatic 
protons interactions and a lot more aliphatic-aromatic protons interactions (Figure 
III.2.3.3-4 B). This could be explained by the fact that the pentamer has a better 
defined structure compared to the tetramer or that the tetramer has a correlation time 
such that the NOE are less intense.  Moreover, we examined the chemical shifts of 
the amide protons of the first and second DBT residues (Figure III.2.3.3-5). The 
chemical shift of the amide proton of the first residue is constantly shifted up-field 
when we elongate the oligomer until we reach the pentamer and is slightly down-
fielded from the pentamer to the octamer. The amide proton signal of the second 
residue is at first shifted down-field between the monomer and the trimer, then it is 
shifted up-field until the pentamer but its chemical shift is constant from the pentamer 
to the octamer. These data suggest the progressive organization of the DBT 
oligomers in DMSO with the elongation of their sequences and the formation of well 
defined secondary structure starting from the DBT pentamer. These observations 
were supported by the different NOE patterns observed for the tetramer and the 
pentamer (Figure III.2.3.3-4).  
 
We decided to examine more closely the Ac-(DBT)6-NH2 NOESY spectrum 
(MT 250ms) obtained in d6-DMSO. In fact this spectrum showed even more NOE 
interactions than the spectrum obtained for the pentamer (Figure III.2.3.3-6). At the 
same time there was not as much overlay as in the case of the heptamer and the 
octamer.  
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Figure III.2.3.3-4 A) NOESY spectrum (MT=250ms) of compound Ac-(DBT)4-NH2. B) 
NOESY spectrum (MT=250ms) of compound Ac-(DBT)5-NH2. 
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Figure III.2.3.3-5 Chemical shifts of the amide protons for DBT oligomers of different length   
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Figure III.2.3.3-6 NOESY spectrum (MT=250ms) of compound Ac-(DBT)6-NH2. 
The Ac-(DBT)6-NH2 spectrum could be separated in four parts: 
-aliphatic-aromatic NOE interactions (red colour on Figure III.2.3.3-6) 
First very important observation was that we did not observe the same artefacts 
as in the case of the ROESY spectra (Figure III.2.3.3-1). Important for the 
determination of the structure are the intense interaction between the HA proton and 
the aromatic protons in the same residue. These interactions suggest a constraint 
and well defined conformation of the DBT residues inside the oligomer. We assigned 
intra-residue interactions between:  
 HD2,3-HE1 and HD2,3-HZ1 in the same residue (valid for all the residues).  
 HB2,3-HE2 and HB2,3-HZ2 in the same residue (valid for all the residues). 
We assigned also some very important inter-residue interactions like:  
 HE1 DBT:B2 with HB2 DBT:B3;  
 HE1 DBT:B1 with HA DBT:B2;  
 HE1 DBT:B1 with HB3 DBT:B2; 
 HD3 DBT:B2 with HB2 DBT:B3; 
Aliphatic/Amide 
Amide/Aromatic 
Aliphatic/Aliphatic Aliphatic/Aromatic 
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 HD3 DBT:B4 with HB2 DBT:B5; 
 HD3 DBT:B3 with HB2 DBT:B4; 
 HZ2 DBT:B2 with HA DBT:B3 
-Aliphatic-aliphatic proton interactions (orange colour on Figure III.2.3.3-6) 
In the ROESY and NOESY spectra of compounds Ac-(DBT)n-NH2 n=[1-4] we 
observed very few aliphatic-aliphatic interactions (Figure III.2.3.3-4 A). In the case of 
Ac-(DBT)6-NH2 2D NOESY spectrum we observed intense aliphatic-aliphatic proton 
interactions but unfortunately due to the overlay it was hard to assign and quantify 
them. Nevertheless these data show the better structural organization of Ac-(DBT)6-
NH2 compared to the shorter oligomers. One of the interactions that we were able to 
quantify was HA DBT:B1 with HB2 DBT:B1. We used the volume of this interaction 
as reference to convert the NOE volumes into distance restriction.   
-Aliphatic-amide proton interactions (purple colour on Figure III.2.3.3-6) 
These interactions are not so important for the determination of the secondary 
structure but were crucial for the assignment of the protons. Some examples for the 
NOEs detected: 
 H DBT:B6 - HD2 DBT:B5;  
 H DBT:B5 - HD2 DBT:B4; 
 H DBT:B4 - HD2 DBT:B3; 
 H DBT:B2 - HD2 DBT:B1; 
 H DBT:B3 - HD3 DBT:B2; 
 H DBT:B6 - HD3 DBT:B5; 
 H DBT:B5 - HD3 DBT:B4; 
 H DBT:B4 - HD3 DBT:B3 
-Aromatic-amide proton (violet colour on Figure III.2.3.3-6) 
These interactions could be very important for the determination of the 
secondary structure. The interactions we detected were of type H DBT:Bi with HE1 
DBT:Bi-1. 
A table with all the measured volumes and distances (with upper and lower 
limits) could be found in the Materials and Methods section (Section V.7.2). While 
measuring the volumes and distances we encountered certain problems. First one 
was the overlay. In case of important overlay between NOEs we considered the 
maximum distance between the protons to be 5.5 Å.  Another problem was that HD2 
and HD3 had similar NOE values with all the other atoms. The same problem was 
observed for protons HB2 and HB3. This problem is often observed for geminal 
protons and usually is solved during the structure calculations by means of the 
introduction of pseudo atoms. 
III.2.3.4 Determination of the secondary structure of Ac-(DBT)6-NH2 by 
molecular modelization with distance restrictions 
The calculated distance restrictions in Ac-(DBT)6-NH2 (reported in section 
III.2.3.3 and Materials and Methods) are currently being used for the determination of 
the oligomer structure by a molecular modelization study.  
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III.3 DBT and AMPA oligomers as cell penetrating non-
peptides (CPNP) 
As mentioned in the introduction (section I.1.2.) foldamers are attractive 
platform for the design of cell penetrating non-peptide compounds (CPNP).3,4 We 
hypothesized that short oligomers constructed by DBT or AMPA frameworks could 
translocate the cellular membrane and thus be used as a new class of CPNP (see 
section I.2.2). Even though these compounds are not charged as most CPP5 or 
CPNP we considered that by virtue of their aromaticity, hydrophobicity and their well-
organized structure they could have a non-specific interaction with the lipid bilayer 
and thus be internalized into the cell. This chapter of the manuscript will mainly focus 
on the ability of these short hydrophobic oligomers to transport fluorescent dyes and 
short linkers inside the cell while in the ‗V‘ chapter we will concentrate on their ability 
to transport biologically relevant cargos like the powerful inhibitor of the Cathepsin D 
- pepstatine.  
III.3.1 Synthesis of oligomers tagged by fluorescein isothiocyanate 
III.3.1.1 Synthesis of short DBT and AMPA oligomers tagged by 
fluorescein isothiocyanate 
Oligomers of different lengths were synthesized (see Materials and Methods) 
on a solid support using RA PS resin, by successive addition of N-Fmoc protected 
DBT/AMPA (Fmoc-DBT-OH/Fmoc-AMPA-OH) in the presence of HBTU as coupling 
reagent and DIEA as a base. In order to track their cellular internalization by 
fluorescence microscopy, fluorescein isothiocyanate was used to label the oligomers 
(Figure III.3.1.1).  
 
Figure III.3.1.1 Synthesis of fluoresceine labelled oligo-(D- and L-BT) and oligo-AMPA 
The fluorescent tag was either directly attached to the N-terminus of the 
poly(DBT)/poly(AMPA) anchored to the resin or attached to the N-terminus via a 
short linker. The importance of the configuration and the structure of the oligomers 
were assessed by the preparation of the LBT derivative (JMV4228) and the D/LBT 
alternated oligomer (JMV4287), respectively. The compounds synthesized following 
this strategy are summarized in Table III.3.1.1 In the case of compound JMV4497, a 
short solubilizing moiety between the CPNP oligomer and the fluorescein was 
introduced. The solubilizing moiety is composed of a short polyethylene glycol linker 
and D-Arg residue. The introduction of such moiety was motivated by the poor 
solubility of the longer AMPA oligomers in aqueous media.  
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Table III.3.1.1 Fluorescein labelled DBT and AMPA oligomers synthesized for internalization 
studies.  
Compounds JMV number 
Fl-(DBT)2-NH2 JMV2949 
Fl-(DBT)3-NH2 JMV2968 
Fl-(DBT)4-NH2 JMV3229 
Fl-(LBT)4-NH2 JMV4228 
Fl-DBT-LBT-DBT-LBT-NH2 JMV4287 
Fl-(AMPA)3-NH2 JMV4236 
Fl-(AMPA)4-NH2 JMV4237 
Fl-O2Oc-r-(AMPA)4-NH2 JMV4497 
 
III.3.1.2 Synthesis of octa and nona-arginine and (DBT)3-4-(Arg)9 
oligomers tagged by fluorescein isothiocyanate 
In order to study the internalization of our set of compounds we needed a 
positive control. As such, we chose the well-studied and potent CPPs octa and nona-
arginine (Section I.2.1). The octa and nona-arginine were synthesized following the 
standard SPPS methodology on RA PS resin with HBTU/DIEA activation. They were 
tagged on the amino-end by fluorescein isothiocyanate via an aminohexanoic acid 
linker in order to avoid secondary reactions reported by Subra et al.74  
Some publications in the literature point that an association of oligo-arginine 
with a hydrophobic moiety could result in a very powerful cell penetrating compound. 
Such compounds could also be used to internalize DNA or SiRNA via the non-
covalent strategy.47 Inspired by these  data, we synthesized via SPPS on RA PS 
resin chimeric oligoDBT-oligoArginine bioconjugates. We linked the DBT trimer and 
tetramer to the nona-Arginine via an Ahx linker and then we tagged the compounds 
by fluorescein. The synthesized arginine oligomers and mixed DBT-Arginine 
oligomers are summarized on Table III.3.1.2. 
Table III.3.1.2.  PolyArginine containing compounds synthesized as positive tests and 
chimerical CPNP 
Compounds JMV number 
Fl-Ahx-(Arg)8-NH2 - 
Fl-Ahx-(Arg)9-NH2 JMV3888 
Fl-Ahx-(DBT)3-Ahx-(Arg)9-NH2 JMV4568 
Fl-Ahx-(DBT)4-Ahx-(Arg)9-NH2 JMV4569 
 
III.3.2 Internalization of short DBT oligomers tagged by fluorescein  
III.3.2.1 Cellular Uptake of DBT Oligomers by MDA-MB-231 breast cancer 
cells. 
At first, the cellular uptake in MDA-MB-231 breast cancer cells of the 
oligomers (JMV2949, JMV2968, JMV3229, JMV4228, JMV4287) was analysed by 
fluorescence emission measurement (Figure III.3.2.1-1 A, See section I.2.3.) and 
compared to fluorescein labelled octa-arginine (Arg8) as a positive control and 
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carboxyfluorescein (CF) as a negative control. In order to determine the internalized 
fraction of the compounds, a 5-min trypsin treatment was realized to remove 
membrane-bound transduction compounds. It is worth noting that the percentage of 
membrane-bound DBT oligomers was not as important as in the case of the Arg8. 
Probably this polycationic compound has a higher affinity for the lipid membrane via 
its association to the anionic phospholipids and proteoglycans. The highest 
intracellular fluorescence intensity was found for DBT4 (JMV3229) with a drastic 
decrease (>4-times) for DBT3 (JMV2968) and DBT2 (JMV2949) oligomers. Thus, the 
cellular uptake appeared length-dependent with an increase of internalization with 
the oligomer size. Moreover, the amount of DBT4 that was internalized was more 
significant than that of Arg8 despite the fact that it is uncharged. Even though the 
increase in efficiency from DBT2 to DBT4 could be associated with an increase of the 
hydrophobicity, the high difference between DBT3 and DBT4 might be also attributed 
to a progressive organization of the oligomer structure. Compound LBT4 (JMV4228) 
constructed by the oligomerization of an L-benzothiazepinone moiety was as potent 
as its D-counterpart suggesting that the configuration of the BT moiety was not 
important and that the CPNPs do not interact with a specific receptor but rather with 
hydrophobic plasma membrane components. Compounds constructed from the 
alternation of D and LBT exhibited a 2-times decreased uptake. This result could be 
explained by a change in the oligomer structure.  
A dose-response analysis was performed to compare the uptake of the BT-
oligomers with octa-arginine (Figure III.3.2.1-1 B). The penetration of all compounds 
appeared to be dose-dependent. However in contrast to Arg8, uptake of JMV 
compounds still increased at high doses (5.10-5 M). The kinetics study performed with 
10-5 M JMV3229 (III.3.2.1-2 A) showed that its cellular entry was at least as efficient 
at 1 h as that of Arg8. Then, JMV3229 uptake increased up to 16 h to reach a 6-time 
higher intracellular concentration than Arg8, for which maximal concentration is 
reached at 1 h. A temperature-dependent analysis performed at 4°C and 37°C 
(III.3.2.1-2 B) showed that the cellular uptake exhibited a 3-times decrease at low 
temperature, hence suggesting the involvement of an energy-dependent endocytotic 
pathway. The remaining fluorescence was most probably due to cell membrane-
bound oligomers as shown in Figure III.3.2.2 D.  
III.3.2.2 Intracellular Distribution of DBT Oligomers. 
Confocal laser scanning microscopy (CLSM) (see section I.2.3) analyses were 
also performed on living MDA-MB-231 cells to assess internalization and intracellular 
distribution. These experiments were associated with a kinetic study of Fl-(DBT)4-
NH2 oligomer internalization. Figure III.3.2.2 A shows the internalization of JMV3229 
in cellular organelles after 3 h of incubation with the highest accumulation at 16 h and 
an apparent decrease at 24 h in accordance with the kinetic study reported in Figure 
II.3.2.1-2 A. Co-staining with a membrane marker (lipid-raft labelling) indicated that 
this hydrophobic compound was not held in the lipid membrane at 37°C. However, at 
4°C, the majority of the compound was co-localized with the membrane marker 
(Figure III.3.2.2 D) rather than internalized, confirming the temperature effect on the 
intracellular uptake described in Figure III.3.2.1-2 B and supporting an energy-
dependent internalization mechanism.  
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Figure III.3.2.1-1 Uptake of Arg8 and DBT oligomers in MDA-MB-231 cells. Data are the 
means ±SD from three independent experiments. In B) cells were treated by trypsin before 
fluorescence measurements. A) Determination of total and internalized compounds after 
incubating cells for 3 h at 37 °C with 10-5 M of fluorescently labelled compounds. *p < 0.05, 
**p < 0.01 relative to Arg8 values with or without trypsin treatment, respectively (Student’s t 
test). (B) Comparison of fluorescence emission after incubation for 3 h with several 
concentrations ranging from 10-6 to 5.10-5 M. *p < 0.05, **p <0.01 relative to Arg8 values at 
the same concentration (Student’s t test). 
 
 
 
Figure III.3.2.1-2 A) Kinetics of internalization of JMV3229 and Arg8 at 10
-5 M.  
B) Effect of temperature on the cellular uptake of JMV3229 at 3 h.  
 
To gain more insight into JMV3229 internalization, co-stainings were performed with 
other fluorescent markers for subcellular components such as the nucleus, 
endosomes, and lysosomes. The results showed that JMV3229 was mostly co-
localized with an endosomal marker at 3 h (Figure III.3.2.2 B) and with a lysosomal 
marker at 16 h (Figure III.3.2.2 C). Similar data were obtained for the L-counterpart 
JMV4228. This indicated an endosomal uptake of these oligomers followed by a 
lysosomal accumulation. 
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Figure III.3.2.2 Confocal microscopy images of living MDA-MB-231 breast cancer cells 
incubated with JMV3229 compound at 10-5 M concentration. Images are representative of at 
least 3 independent experiments. A) Distribution of JMV3229 after 3, 16, and 24 h of 
incubation at 37°C. B) Co-localization of JMV3229 with the endosomal marker at 3 h at 37°C. 
C) Co-localization of JMV3229 with the lysosomal marker at 16 h at 37°C D). Distribution of 
JMV3229 at 4°C and co-localization of the oligomers with the membrane marker. 
 
III.3.2.3 Toxicity of the DBT oligomers 
The cytotoxicity of this new class of molecules was also determined in MDA-
MB-231 cells by using MTT viability assay (Figure III.3.2.3 and Materials and 
Methods). After a 5 day-incubation, these compounds exhibited no significant effect 
on the cell viability at 10-5 M concentration. These results indicated that oligoDBTs 
could be safely used as vectors for cell drug delivery. 
 
 
Figure III.3.2.3 MTT cell viability assay.  Cytotoxicity of compounds after a 5-day incubation 
at a concentration of 10-5 or 10-6 M. Values are mean ± SD of three independent experiments 
performed in triplicates. Values are expressed as a percentage of control cells incubated with 
vehicle alone (1% DMSO). 
A 
B 
C 
D 
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III.3.2.4. Cellular uptake of DBT oligomer by different cell lines 
To assess the capacity of DBT oligomers to be internalized by different cell 
lines we performed internalization tests with prostate, colon, osteosarcome and 
breast (2 types) cancer cell lines (Figure III.3.2.4). The internalization was studied by 
total fluorescence emission measurement. The same pattern of internalization as that 
of MDA-MB-231 was observed for the other tested cell lines. DBT and LBT tetramers 
were internalized in the same manner by all cell lines and they were both better 
internalized than the potent polycationic CPP Arg8.  
 
Figure III.3.2.4. Uptake of Arg8 and DBT oligomers in different cell lines. Total - cells were  
not treated by trypsin before fluorescence measurements. Internalized - cells were treated by 
trypsin before fluorescence measurements. 
III.3.2.5 Discussion  
Altogether, these data indicate the ability of our new class of CPNPs to target 
the endolysosomal pathway. Although most of the initial drug delivery studies aimed 
to avoid lysosomal addressing to prevent subsequent drug degradation, more recent 
studies demonstrated the relevant clinical utility to target this compartment for drug 
delivery in the treatment of lysosomal storage diseases, Alzheimer‘s disease, and 
cancer.9 The described by us CPNPs are characterized by their lack of charge, small 
size, well defined secondary structure, high intracellular uptake and resistance to 
proteases. Their mechanism of internalization is non-specific receptor dependent and 
probably implicates an interaction with the hydrophobic regions of the cell membrane 
like the lipid rafts. While a promising candidate for vectorization of biologically 
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relevant cargos, the DBT oligomers probably share similar drawbacks with the CPPs 
like the lack of cell specificity. 
III.3.3 Internalization of chimeric OligoDBT-OligoArg oligomers tagged by 
fluorescein  
Confocal laser scanning microscopy (CLSM) (see section I.2.3) analyses were 
performed in living MCF7 cells to assess internalization and intracellular distribution 
of compound Fl-Ahx-(DBT)4-Ahx-(Arg)9-NH2 (JMV4569). These experiments were 
associated with a kinetic study of the oligomer internalization (Figure III.3.3 A). The 
experiments were performed at a very low concentration of 10-7 M at 37°C. At the 3th 
hour we observed internalization of the compound with more important accumulation 
at the 16th hour. Co-staining with a membrane (lipid-raft labelling) and nucleus 
markers indicated that the compound was not held in the lipid membrane at 37°C. At 
the same concentration (10-7 M) no internalization of the potent CPP (Arg)9 was 
observed after 16 hours (Figure III.3.3 B) 
 
Figure III.3.3 Confocal microscopy images of living MCF7 breast cancer cells incubated with 
JMV4569 or JMV3888  at 10-7 M. Images are representative of at least 3 independent 
experiments. A) Distribution of JMV4569 after 3 and 16 hours of incubation at 37°C and co-
localization with membrane marker. B) Distribution of JMV3888 after 16 hours of incubation 
at 37°C and co-localization with membrane marker. 
These data shows the high potential of these chimerical compounds as CPNP. 
These oligomers will be tested for their ability to deliver SiRNA via a non-covalent 
strategy. Even though these results are encouraging much work remains to be done 
as total fluorescence emission measurements of the internalization efficiency and in 
vitro tests for SiRNA internalization. 
III.3.4 Internalization of AMPA oligomers tagged by fluorescein 
CLSM analyses (see section I.2.3) were performed in living MDA-MB-231 cells 
to assess internalization and intracellular distribution of compound Fl-O2Oc-r-
(AMPA)4-NH2 (JMV4497). These experiments were associated with a kinetic study of 
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the oligomer internalization (Figure III.3.4 A). The experiments were performed at a 
concentration of 10-5 M at 37°C. At 3 hours we observed internalization of the 
compound with more important accumulation at 16 hours. Co-staining with a 
membrane marker (lipid-raft labelling) indicated that the compound was not held in 
the lipid membrane. At 16 hours a big part of the internalized compound was co-
localized with the lysosome marker (Figure III.3.4 B). 
 
Figure III.3.4 Confocal microscopy images of living MDA-MB-231 breast cancer cells 
incubated with compound JMV4497. Images are representative of at least 3 independent 
experiments. A) Distribution of JMV4497 after 3 and 16 hours of incubation at 37°C and co-
localization with membrane and nucleus marker. B) Distribution of JMV4497 after 16 hours of 
incubation at 37°C and co-localization with lysosome marker. 
These data suggest that (AMPA)4 like the (DBT)4 could be used as a CPNP. 
This compound shares the same non-cationic hydrophobic nature and well organized 
structure as (DBT)4. Both compounds (DBT)4 and (AMPA)4 possess four aromatic 
unites that are probably an important feature for their internalization. Similarly to the 
(DBT)4, (AMPA)4 is delivered to the lysosomes and thus could be used to deliver 
drugs for the treatment of cancer (see section III.5), lysosomal storage disease and 
Alzheimer‘s disease. Moreover, (AMPA)4 is characterized by its even smaller size 
than that of (DBT)4.  
III.4. A Straightforward approach for cellular-uptake 
quantification of CPPs and CPNPs 
III.4.1 Methodology  
Most studies of CPPs or CPNPs internalization efficiency are performed by 
fluorescence emission measurement, FACS display or confocal microscopy (see 
section I.2.3). All these techniques share the same disadvantage – they cannot 
quantify the exact amount of compound internalized per cell or the intracellular 
concentration. Most of the studies are made in comparative manner. New CPP or 
CPNP fluorescence emission is compared to a well-known CPP like TATp or 
oligoArg. To confront this problem Burlina et al. developed a highly reproducible 
quantification method based on MALDI-TOF MS to straightforward measure the 
44 
 
concentration of the internalized peptides (see section. I.2.3).10 Taking advantage 
from our group experience with proteomics studies we designed an improved method 
that does not require any separation or chromatographic steps. Our group has 
previously reported an original approach in which peptides derivatized by α-cyano-4-
hydroxycinnamic acid (HCCA) were readily identified by selective enhancement and 
discrimination of their MALDI TOF MS signals in a neutral matrix, such as α-cyano-4-
hydroxycinnamic methyl ester (HCCE).75 The HCCA moiety is an UV absorbing tag 
that has the property to dramatically enhance the relative MALDI TOF MS signal 
strength of the compounds it is attached to. The HCCE matrix has the property to 
reduce the MS signal strength of all the compounds except the ones that are tagged 
by the HCCA moiety. This combination (HCCA tag and HCCE matrix) enabled us to 
discriminate signals induced by peptides of interest that were present in low 
concentrations from those of unlabelled more abundant peptides. To quantify the 
compounds after their internalization we synthesized deuterated ‗heavy‘ HCCA(D4) 
(Figure III.4.1-1). 
 
Figure III.4.1-1 Synthesis of deuterated HCCA(D4) protected by Boc group on the hydroxyl 
function 
 
CPPs/CPNPs were prepared by microwave assisted solid-phase synthesis on RA PS 
resin coupled with light (D0) or heavy (D4) HCCA on their N-terminus through an 
aminohexanoic acid (Ahx) spacer (Figure III.4.1-2 A). The ability of these compounds 
to penetrate cells was readily determined by comparison of the MS signals induced 
by tagged compounds with those of the over-represented untagged materials. Thus, 
no separation procedure was required. The material that penetrated cells was 
quantified by comparison of the signals due to the light tag with the corresponding 
signals of the deuterated heavy HCCA. The methodology (described in Figure III.4.1-
2 B) was validated by using four different compounds: the two widely used CPPs 
penetratin and nona-arginine (Arg)9 (see section I.2.1), our potent CPNP (DBT)4 
(described in section III.3.2)   and a tripeptide (FAK) as a negative control (Table 
III.4.1).  
 
Initially to prove our concept we checked that HCCA-tagged peptides could be 
detected in a crude cell lysate by MALDI-TOF MS up to a 10-10 M, which corresponds 
to the possible concentration of internalized compound in the sample after cell lysis.10 
To highlight the HCCE/HCCA matrix-discrimination effect, N-terminal acetylated 
peptides were prepared and mixed at different concentrations along with HCCA-
tagged peptides in a crude cell lysate. Equimolar mixtures of HCCA-CPPs and Ac-
CCPs diluted in water/acetonitrile were mixed in a cell lysate to afford a 5.10-6 M to 
5.10-11 M concentration of each peptide species.  
The samples were prepared either in an HCCA matrix or in a neutral HCCE matrix to 
assess the discrimination effect (see Figure III.4.1-3). The MALDI-TOF spectra were 
quite clean, and very few signals were observed from the cell lysate or the buffer. 
HCCA tagged peptides were still readily detected at 5.10-9 M in the HCCA matrix and 
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5.10-10 M in the HCCE matrix. Ac-CPPs with the exception of Ac-(DBT)4-NH2 were 
not detected at a concentration of 5.10-8 M in HCCE matrix (Figure III.4.1-3) 
 
 
 
 
Figure III.4.1-2 A) Synthesis of light (D0) and heavy (D4) HCCA-tagged CPPs. B) Strategy 
for the direct quantification of the cellular uptake of CPPs (and a CPNP) by MALDI-TOF MS 
by using the HCCA/HCCE discrimination effect: a) incubation of cells with the HCCA-tagged 
CPP; b) washing step; c) enzymatic stripping of the cell membrane; d) lysis of cells, followed 
by the addition of a precise amount of the deuterated-HCCA-tagged CPP as an internal 
standard; e) MALDI-TOF analysis of the whole cell lysate in the HCCA matrix; f) MALDI-TOF 
analysis of the whole cell lysate in the “neutral” HCCE matrix. The HCCA/HCCE signal-
discrimination effect enables the enhancement of the CPP/CPNP signal in a complex 
mixture. The internalized CPP can be quantified on the basis of the ratio between the [M+H] + 
peaks of the deuterated and nondeuterated HCCA-tagged CPP.  
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Table III.4.1 Compounds tested for cellular uptake. Mass spectrometry intracellular uptake 
concentration results. 
*Intracellular uptake concentration reported in the publication of Burlina et al.10 using biotin labelled 
analogues 
 
Figure III.4.1-3 MALDI-TOF MS spectra of equimolar mixtures of Ac- and HCCA-penetratin 
(5.10-8 M each) in cell lysate. Above spectrum was obtained in HCCA matrix and the down 
spectrum in HCCE matrix. 
 
Generally, the HCCA-discriminating effect increased when the concentration 
of the analyte (HCCA-CPP or Ac-CPP) decreased. This phenomenon makes HCCA 
tagging a method of choice for the detection and quantification of low abundance 
compounds in a complex mixture. Furthermore, the baseline of spectra obtained in 
the HCCE matrix was flatter than that of spectra obtained in the HCCA matrix. This 
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Intracellular 
uptake 
Intracellular 
Uptake* 
Penetratin  
1a 
1b 
1c 
Ac- 
HCCA- 
HCCA(D4)- 
-Ahx-
RQIKIWFQNRRMKWKK-
NH2 
2400.4 
2529.4 
2533.4 
2422.4 
2551.4 
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11.21 μM 3 3.5 µM 
(Arg)9 
2a 
2b 
2c 
Ac- 
HCCA- 
HCCA(D4) 
-Ahx-RRRRRRRRR-NH2 
1578.0 
1707.0 
1711.0 
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11.08 μM 4 4.5 µM 
(DBT)4 
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      -Ahx-(DBT)4-NH2 
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flat baseline is particularly favourable for the purpose of peak integration and 
quantification. The expected discrimination effect was less significant with the (DBT)4 
sequence: the intensity of the Ac-Ahx-(DBT)4-NH2 [M+Na]
+ peak at m/z 1131.3 was 
only two times lower than that of the HCCA-Ahx-(DBT)4-NH2 [M+Na]
+ peak at m/z 
1260.4 in the HCCE matrix (see Figure III.4.1-4)  The DBT moiety is probably able to 
absorb UV light in a similar manner as that of the HCCA moiety.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.4.1-4 MALDI-TOF Mass spectra of equimolar mixtures of Ac- and HCCA-(DBT)4 
(5.10-8 M each) in cell lysate. The above spectrum was obtained in HCCA matrix and the 
down spectrum in HCCE matrix. 
 
Once that we confirmed that HCCA tagged CPP and CPNP could be detected 
in very low concentration in complex mixtures we moved to in vitro tests. 
Internalization experiments were performed on the MDA-MB-231 cell line according 
to the modified protocol described by Burlina et al.10 (Figure III.4.1-2 B). The HCCA-
tagged compounds 1b, 2b, 3b, and 4b were incubated at a concentration of 10 μM 
with 2.105 MDA-MB-231 breast cancer cells for 3 hours at 37  C. The biological 
samples were then split into two pools to be submitted or not to trypsin stripping of 
cell-membrane-bound CPPs (see section I.2.3). The cells were lysed for 20 minutes 
with lysis buffer containing 2-amino-2-hydroxymethylpropane- 1,3-diol (Tris) and 
ethylenediaminetetraacetic acid (EDTA), and the membrane fragments were 
removed by centrifugation. The supernatant was collected and added to known 
amounts of the corresponding deuterated CPP. In this way, both internalized CPPs 
and internal standards ([D4]HCCA-labelled CPPs) were exposed to degradation by 
proteases remaining in the medium.  
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The samples were deposited directly on the MALDI probe, mixed with a HCCA or 
neutral HCCE matrix, and analysed. Spectra were averaged for statistical sampling 
from a hundred laser shots recorded on different spots of the deposit. Figure III.4.1-5 
gives a good idea of the HCCA/HCCE discrimination effect on HCCA tagged CPPs. 
Acetylated and HCCA-tagged Penetratin (1a and 1b respectively) were submitted to 
internalization tests. They were both analysed in HCCA or HCCE matrix. Compound 
1a was only hardly detectable in the cell lysate in HCCA matrix, while 1b was 
detectable in HCCA matrix and represented the major MS peak in HCCE matrix. 
 
 
Figure III.4.1-5 MALDI TOF MS spectra of internalized Ac-Ahx-penetratine and HCCA-Ahx-
penetratine. Samples were obtained in HCCA or HCCE matrix. 
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The spectra obtained in HCCE matrix were used for the peak integration and 
quantification as they gave better signal to noise ratio. The areas of all isotope peaks 
of the light and heavy compounds corresponding to mono-protonated compounds 
[M+H]+ were used for quantification. In the case of DBT derivatives (Table III.4.1, 3b 
and 3c), the isotope peaks of the sodiated ions [M+Na]+ were chosen for 
quantification, as they are more intense than those of the mono-protonated ions. The 
mass increment of 4 Da between the compounds tagged with light HCCA and heavy, 
isotopically labelled [D4] HCCA gave two isotopic distributions that partially 
overlapped at the edges. For example, the ion at m/z 2533.6 in Figure III.4.1-6 was 
produced by the cumulated contributions of the light-HCCA tagged molecule 
containing four naturally occurring 13C atoms (very tiny abundance) and of the heavy-
[D4] HCCA tagged counterpart (major intensity). The ratio of these two isotopic 
contributions was estimated and taken into account in all results after calculation and 
integration of the isotopic patterns by using the algorithm SNAP (Sophisticated 
Numerical Annotation Procedure) from the software FlexAnalysis. This algorithm 
helped us to determine and separate the exact isotopic pattern of molecules tagged 
with light and heavy HCCA, even when overlapping occurred. 
 
 
Figure III.4.1-6 Quantification of HCCA-Ahx-penetratin (1b) through the addition of its 
deuterated counterpart at a concentration of 10-9 or 10-10 M (samples were prepared in an 
HCCE matrix). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.4.1-7 Quantification of HCCA-Ahx-(Arg)9 2b using its deuterated counterpart 
introduced at 10-9 M concentration in the sample (samples were prepared in HCCE matrix) 
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The absolute quantification was more precise when light and heavy compounds 
displayed similar intensities and thus similar concentrations in the sample.  
 
A logarithmic range of concentrations of the deuterated standards was used to 
determine accurate concentration values. Each CPP concentration was calculated by 
using the more accurately known concentration values of the [D4]HCCA-tagged 
compound. 
 
 
Figure III.4.1-8 Quantification of HCCA-Ahx-(DBT)4 (3b) through the addition of its 
deuterated counterpart at a concentration of 10-7 or 10-8 M (samples were prepared in an 
HCCE matrix). 
 
Quantification was performed with ratios varying from 0.1:1 to 4:1. The analysis of 
several deposits of the same cell lysate yielded highly reproducible results (a 
maximum of 10% variation between samples). The analysis of different deposits of 
various biological samples (cell lysates with a variable number of MDA-MB-231 cells) 
also showed good reproducibility. By using this protocol, we calculated the 
intracellular concentration of the four compounds (Table III.4.1). A concentration of 
1.21 μM for the penetratin derivative 1b was found (see the spectrum used for 
quantification on Figure III 4.1-6) and 1.08 μM for the (Arg)9 derivative 2b (see the 
spectrum used for quantification on Figure III 4.1-7). These two values are in full 
accordance with the previously reported MS quantification of N-terminally biotinylated 
CPPs. As expected, the negative-control peptide 4b was not detected in the cell 
lysate; the internal standard 4c was detected at a concentration of 10-8 M. The 
highest intracellular concentration (8.70 μm) was found for the labelled (DBT)4 CPNP 
3b (see the spectrum used for quantification on Figure III 4.1-8). This value 
corresponds to an absolute amount of 13.10-18 Mol in a single cell. 
 
The experiments were repeated with the pool of trypsin untreated cells. A 
comparison of the two series reflected the proportion of the CPP (or CPNP) that 
remained bound to the membrane. Depending on the CPP (or CPNP), the amount of 
internalized compounds was 10–100 times lower after trypsin treatment (Figure 
III.4.1-9). We should note that in the case of the CPNP (DBT)4 this difference was 
less important probably due to its non-cationic character. 
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Figure III.4.1-9 Amount of compounds detected after incubation of compounds 1b, 2b, 3b 
with MDA-MB-231 cells and lysis of the cells. Stripped bars and gray bars correspond to cells 
submitted or not to five minutes trypsin treatment, respectively. Negative control 4b is not 
presented in the figure as no peptide was detected. 
III.4.2 Discussion 
We have described a straightforward and efficient method for the 
quantification of cell-penetrating compounds internalization. The originality of the 
methodology relies first on the use of the combination of HCCA as a UV-light-
absorbing tag and the neutral HCCE matrix, which enabled the very sensitive 
detection of the compounds of interest by mass spectrometry even in complex 
biological samples, and second on the stable isotope labelling of such compounds for 
their reliable quantification. The procedure does not require any purification step, 
including biotin-based capture. The later is extremely important and makes this 
method one of the most simple and precise reported in the literature. Like some of 
the fluorescence emission measurement techniques, this method should be used in 
combination with confocal microscopy. This combination gives the possibility to 
determine the localization and the exact intracellular concentration of the CPP/CPNP. 
The results obtained with (DBT)4 and (Arg)9 are in complete agreement with the 
fluorescence-based assays reported in section III.3 and further affirmed the 
importance of the DBT tetramer as a powerful CPNP. 
 
III.5 Vectorization of pepstatine – in vitro inhibition of the 
Cathepsine D and anti-cancer activity 
 
As mentioned in section I.3, Cathepsin D (CD) has complex role in the cancer 
development probably via its enzymatic activity inside the endosomes or the 
lysosomes but also as a ligand to a yet unknown extracellular receptor. Some groups 
have studied the inhibition of Cathepsin D in vitro by incubation of cancer cells with 
pepstatine. Even though pepstatine is a powerful transition state inhibitor of the CD, it 
had no effect on the cell growth. The lack of inhibitory activity should be attributed to 
the fact that pepstatine has very poor solubility in water and is unable to penetrate 
into the cells.69 Thus, it appeared crucial to study the CD inhibition in vitro and in vivo 
0
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by vectorized pepstatine. Such study was of a considerable interest because it 
should allowed us to:  
 
- Study the importance of CD enzymatic activity for the cancer development 
- Prove that our set of CPNP is able to traffic biologically relevant cargos 
- Find potent anti-breast cancer compounds 
 
A perfect vector for the pepstatine is one that directs the compound to the 
endosomes and the lysosomes – the cell compartments where CD enzymatic activity 
is the most important. Thus oligo-AMPA and oligo-DBT have seemed particularly 
attractive candidates for the vectorization of the pepstatine because of their ability to 
deliver fluorescent dyes to the endosomes and the lysosomes (See sections III.3.2 
and III.3.4).  
 
III.5.1 CD vectorized inhibitors design 
 
The first set of vectorized pepstatine inhibitors that we synthesized were the 
compounds Pepstatine-(Arg)9-NH2, Pepstatine-(AMPA)4-NH2 and Pepstatine-(DBT)4-
NH2 (table III.5.1 A). As vectors, we used our CPNP (AMPA)4 and (DBT)4 (see 
sections III.3.2 and III.3.4) and the well studied CPP nona-arginine. These 
compounds and all following CD inhibitors were synthesized by standard SPPS on 
RA PS resin by HBTU/DIEA activation (see Materials and Methods). From this first 
generation of vectorized CD inhibitors only Pepstatine-(AMPA)4-NH2 showed any 
toxicity in vitro while all compounds were active on the secreted CD enzyme. One of 
the possible explanations for the poor activity of Pepstatine-(Arg)9-NH2 could be the 
fact that this small peptide is internalized to the cytosol instead of the endosomes or 
the lysosomes. While promising, the Pepstatine-(AMPA)4-NH2 bioconjugate has a 
poor solubility which hampered the reproducibility of the biological results. Effectively, 
it is stated that one of the reasons for the low anti-tumoral activity of the potent 
pepstatine CD inhibitor in vitro or in vivo is its low solubility in water.69 To overcome 
this problem we synthesized a new set of vectorized pepstatine analogues connected 
to a solubilizing moiety on their N-terminus. As a solubilizing moiety we used short 
polyethylene glycol linker 8-amino-3,6-dioxaoctanoic acid (O2Oc) and polar D-amino 
acids residues like D-Asp, D-Lys and D-Arg. We used D-amino acids because of 
their resistance to protease degradation. These compounds are summarized on table 
III.5.1 B. All of these oligomers showed medium to high cytotoxicity with the 
exception of compound Ac-D-Asp-O2Oc-pepstatine-(AMPA)4-NH2 which showed no 
toxicity at all. The most toxic compounds were JMV4463 (Figure III.5.1) and 
JMV4622. Encouraged by this result we synthesized a similar compound to JMV4463 
but vectorized by (DBT)4 instead of (AMPA)4. To our surprise this bioconjugate was 
not toxic (table III.5.1 C). We also synthesized bioconjugates as negative controls 
that includes:  
 
-Compounds JMV4564 and JMV4674 analogues of JMV4463 in which statine 
moieties were substituted by γ-Leu or γ-Ala. The hydroxyl groups of the statine 
moieties are crucial for the CD inhibition so these compounds were supposed to be 
lesser inhibitors of the CD and non-toxic or less toxic in vitro.  
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-Compounds JMV4456 and 4457, analogues of JMV4463 that are devoid of the 
important for the internalization CPNP (AMPA)4 moiety. These compounds were 
designed to be good inhibitors of the isolated CD but non-toxic in vitro. 
 
Lastly, we synthesized a set of fluorescently labelled vectorized CD inhibitors to 
study their internalization potency (Table III.5.1 E). The fluorescein tag was 
connected to the N-terminus of the compounds via a β-Ala moiety so we can avoid 
side reactions as the one reported by Subra et al.74 
 
All the bioconjugates that have been synthesized, their cytotoxicity and CD inhibiton 
results are reported in Table III.5.1. 
 
 
 
 
Figure III.5.1 Compound JMV4463 – a bioconjugate composed of 3 distinctive parts. In red 
the CPNP (AMPA)4 developed by our group, in blue the potent Cathepsin D inhibitor - 
pepstatine and in green a solubilizing moiety. 
  
Table III.5.1 Summary of the Bioconjugates synthesized to study the vectorization of the 
pepstatine 
JMV 
Number 
Compound Cytotoxicity* CD 
Inhibition** 
A) First generation of vectorized pepstatine: Pepstatine-vector 
JMV2719 IsoVal-(Val)2-Sta-Ala-Sta-(AMPA)4-NH2 Inconsistent 
results  
Strong 
JMV4216 IsoVal-(Val)2-Sta-Ala-Sta-(AMPA)3-NH2 None Strong 
 IsoVal-(Val)2-Sta-Ala-Sta-(DBT)4-NH2 None Strong 
 IsoVal-(Val)2-Sta-Ala-Sta-(Arg)9-NH2 None Strong 
B) Second generation of vectorized pepstatine: Solubilizing moiety-
Pepstatine-oligoAMPA 
JMV4461 Ac-D-Lys-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)4-NH2 
High Strong 
JMV4462 Ac-D-Lys-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)5-NH2 
High Strong 
JMV4463 Ac-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)4-NH2 
High Strong 
JMV4464 Ac-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)5-NH2 
High Strong 
JMV4622 H-D-Arg-(Val)3-Sta-Ala-Sta-(AMPA)4-NH2 High Strong 
JMV4623 Ac-D-Arg-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta- Medium Strong 
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(AMPA)4-NH2 
JMV4624 Ac-O2Oc-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)4-NH2 
Medium Strong 
 
JMV4625 
 
Ac-D-Asp-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)4-NH2 
 
None 
 
Strong 
C) Second generation of vectorized pepstatine: Solubilizing moiety-
Pepstatine-oligoDBT 
JMV4630 Ac-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-(DBT)4-
NH2 
None Strong 
D) Negative controls - compounds that are supposed to be less toxic or 
non-toxic in vitro 
JMV4215 IsoVal-(Val)2-γ-Leu-Ala-γ-Leu-(AMPA)4-
NH2 
None Medium 
JMV4563 Ac-D-Lys-O2Oc-(Val)3-γ-Leu-Ala-γ-Leu-
(AMPA)4-NH2 
Medium Medium 
JMV4564 Ac-D-Arg-O2Oc-(Val)3-γ-Leu-Ala-γ-Leu-
(AMPA)4-NH2 
Medium Medium 
JMV4674  Ac-D-Arg-O2Oc-(Val)3-γ-Ala-Ala-γ-Ala-
(AMPA)4-NH2 
None None 
JMV4566 Ac-D-Lys-O2Oc-(Val)3-Sta-Ala-Sta-NH2 None Strong 
JMV4567 Ac-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-NH2 None Strong 
E) Fluorescently labelled compounds for internalization testes 
JMV4626 Fl-β-Ala-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)4-NH2 
None Strong 
JMV4629 Fl-β-Ala-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-
(DBT)4-NH2 
None  Strong 
 
JMV4631 Fl-β-Ala-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-
NH2 
None  Strong 
JMV4632 Fl-β-Ala-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)5-NH2 
None  Strong 
JMV4659 Fl-Ahx-D-Arg-O2Oc-(Val)3-Sta-Ala-Sta-
(AMPA)4-NH2 
None Strong 
 
* Cytotoxicity is classified as: High – IC50 of the cell growth in the range of 10
-6 M to 10-5 M, 
Medium IC50 of the cell growth in the range of 10
-5 M to 5. 10-5 M, None IC50 of the cell 
growth higher than 5.10-5 
** CD inhibition is classified as: Strong - residual CD proteolytic activity between 0 and 20%, 
Medium residual CD proteolytic between 20 and 60%, None residual CD proteolytic activity 
between 60 and 100%, 
  
III.5.2. Test for inhibition of the isolated CD enzyme 
 
Our first task was to asses if the vectorized pepstatine analogues have kept 
their ability to inhibit CD. Figure III.5.2-1 shows the remaining proteolytic activity of 
the CD after incubation with different inhibitors and negative controls calculated by 
the method described in section I.3.2. All the compounds that possess the typical 
pepstatine moiety (JMV4567, 4463, 4626 and 4630) have high inhibition activity. In 
fact they seem to inhibit CD with higher efficiency than the simple pepstatine. This 
should be attributed to their better solubility in water. Compound JMV4564 with 
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statine moieties substituted by γ-Leu showed an intermediate inhibition, while 
compound JMV4674 in which the statine moieties were substituted by γ-Ala exhibited 
practically no inhibition. These results should be explained by the fact that pepstatine 
is a transition-state inhibitor of the CD in which the hydroxyl function of the statine 
residues were expected to give a tight interaction with the enzyme. 
 
 
Figure III.5.2-1 Remaining proteolytic activity of CD incubated with different inhibitors and 
negative controls at 10-5 M. As control we used 1 % DMSO solution in H2O. 
 
These two compounds are very important negative controls because they are 
supposed to show reduced toxicity compared to JMV4463 during the in vitro 
experiments. Compounds JMV4497 and JMV4657 devoid of a pepstatine moiety, 
also tested as negative controls, did not show any inhibition of the CD activity. 
Proteolytic activity of the CD after incubation at 10 μM with the second generation of 
vectorized pepstatine derivatives (Table III.5.1-1 B) is reported in Figure III.5.2-2. The 
solubilizing moieties attached to the N-terminus of JMV2719 to produce the second 
generation of inhibitors did not affect the CD inhibition.  
 
 
Figure III.5.2-2 Remaining proteolytic activity of the CD after incubation with the second 
generation of vectorized pepstatine derivatives at 10-5 M (table III.5.1-1 B). The solubilizing 
moieties attached to the N-terminus did not diminish the CD inhibition by the pepstatine 
moiety. As control we used 1 % DMSO solution in H2O. 
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These data showed that neither attachment of an oligo-AMPA or oligo-DBT as CPNP 
at the C-terminus of pepstatine nor the introduction of hydrophilic moieties or 
fluorescent dyes at the N-terminus diminish its ability to inhibit CD. However, any 
modifications of the pepstatine gave inhibitors with lower efficiency. The ability of all 
the tested compounds to inhibit CD is summarized in Table III.5.1. 
III.5.3. In vitro tests for cytotoxicity  
 
As mentioned in III.5.1 our first positive results for cytotoxicity in vitro were 
obtained with compound JMV2719 but probably due to its poor solubility these 
results were inconsistent. To confront this problem we synthesized a series of 
compounds derivatized with solubilizing moieties on their N-terminus. JMV4622-
4625, JMV4463 and pepstatine were incubated with MDA-MB-231 cells at 10 μM. 
The negative control was 1% solution of DMSO. Cell growth was measured after five 
days of incubation (Figure III.5.3-1). Pepstatine alone, as expected exhibited no 
cytotoxicity, probably due to its inability to cross the cellular membrane. Compounds 
4463 and 4622 exhibeted remarkable toxicity completely inhibiting the cell growth 
after five days. The similarity of the toxicities of compounds 4463 and 4622 showed 
that the polyethylene glycol linker is not crucial for the activity. Compounds 4624 and 
especially 4625 were less toxic probably due to their lower solubility in aqueous 
media. Compound 4623 with two D-Arg residues showed an intermediate toxicity. It 
is possible that too many charged residues hamper the internalization of this 
compound.  
 
 
Figure III.5.3-1 Cytotoxicity of the second generation of vectorized pepstatine inhibitors. 
Growth of MDA-MB-231 cells was measured after five day of incubation at 10 μM 
concentration. As control we used 1% DMSO solution in H2O. 
 
Next we studied the importance of the charged amino acid in the solubilizing 
moiety and the length of the AMPA oligomer. Different cell lines were incubated with 
compounds JMV4461, JMV4462, JMV4463 and JMV4464 at 10μM. The cell growth 
was calculated after 5 days and compared to the cell growth after incubation with 
pepstatine (Figure III.5.3-2). The compounds were especially toxic to the two breast 
cancer cell lines (MDA-MB-231 and MCF7) but showed high cytotoxicity to all the cell 
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cultures.  The HCT116 cell line seems to be less sensitive to these compounds. 
Altogether there was no significant difference between the toxicity of the tested 
compounds. This fact indicates that the nature of the charged group in the 
solubilizing moiety (amino or guanidino) does not influence the activity of the 
compounds. 
 
 
Figure III.5.3-2 Cytotoxicity of pepstatine moiety connected to different CPNP and 
solubilizing moieties. Growth of different cell lines was measured after five days of incubation 
at 10 μM. As control we used 10 μM concentration of pepstatine. 
 
Next we incubated MDA-MB-231 cells with different concentrations of 
compounds JMV4462-4665, JMV4463 and pepstatine in order to calculate their IC50 
after five days of incubation (Figure III.5.3-3). Oligomers JMV4463 and 4622 were the 
most efficient compounds with an IC50 equal to 2 and 3.10
-6 M respectively. We 
chose JMV4463 as a leading compound for its high cytotoxicity and good solubility in 
water. Cytoxicity of this compound was further evaluated on prostate cancer cells, 
colon cancer cells, osteosarcome and two types of breast cancer cells and compared 
to compounds JMV4564, JMV4463, JMV4567 and pepstatine (Figure III.5.3-4). 
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Figure III.5.3-3 IC50 values of vectorized pepstatine inhibitors and negative controls on MDB-
MB-232 cells growth after five days. As control we used 1 % DMSO solution in H2O. 
 
As we expected pepstatine showed no cytotoxicity for all cell lines. JMV4463 
was highly toxic for all cell lines. The HCT116 cells seemed more resistant to this 
compound compared to the others. Compound JMV4567 carrying water-solubilizing 
moiety ‗Ac-O2Oc-r-‗ but free of CPNP was non toxic for all the cell cultures. This 
result showed that the solubilizing moiety is not enough for the toxicity of the 
bioconjugates. Compound JMV4564 is a weaker inhibitor of the CD compared to the 
JMV4463 because of the substitution of its two statine moieties by γ-Leu. This 
compound showed reduced cytotoxicity compared to JMV4463 which is in 
accordance with its lower CD inhibition activity.  
 
 
Figure III.5.3-4 Cytotoxicity of JMV4463, 4564, 4567 and pepstatine to different cell lines 
incubated at 10 μM for   days. As control we used 1 % DMSO solution in H2O. 
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We also incubated MDA-MB-231 cancer cells for five days at different concentration 
of JMV4463, JMV4567, JMV4463, JMV4674 and Pepstatine in order to determine 
their IC50 values (Figure III.5.3-5) 
 
 
 
Figure III.5.3-5 IC50 values of JMV4463 and negative controls on MDB-MB-232 cells growth 
after five days. As control we used 1 % DMSO solution in H2O. 
 
The only compound that showed considerably toxicity was JMV4463. The weaker CD 
inhibitors JMV4674 and 4564 showed very limited inhibition of the cell growth. 
Compound 4567 devoid of AMPA oligomer and wild-type pepstatine were also non-
toxic. This study shows the importance of the pepstatine and the CPNP – (AMPA)4 
moieties for the toxicity. There is a good correlation between the ability of the 
compounds to inhibit CD and their cytotoxicity. Compounds devoid of CPNP are non-
toxic that should be ascribed to lack of penetration and thus their inability to reach the 
endosomes and the lysosomes.  
 
Next a kinetic study of the JMV4463 cytotoxicity was performed. MDA-MB-231 
cells were incubated with 10 μM of JMV4463 or different negative controls (Figure 
III.5.3-6). The cell growth was controlled after 2 hours, 9 hours and 5 days. After two 
hours treatment JMV4463 already showed considerable inhibition of the cell growth 
compared to the control (1% DMSO) while the other compounds showed no toxicity 
with the exception of JMV4564 that showed weak inhibition of the cell growth. After 9 
hours of incubation the cells treated with JMV4463 were less than the seeding and 
about 20% of the control while the cell growth after incubation with the control 
compounds was only slightly inhibited. After five days of incubation with JMV4463 the 
number of cells in the essay was about half of the seeding number and about 15% of 
the control. From the negative controls only the pepstatine showed noticeable toxicity 
- cell growth about 80% of the control after 5 days. Altogether these results show the 
ability of JMV4463 to inhibit completely cell growth for less than 10 hours and to keep 
it lower than the seeding after 5 days. 
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Figure III.5.3-6 Kinetic study of the JMV4463 toxicity compared to different negative controls. 
MDA-MB-231 cells were incubated with 10 μM concentration. As control we used 1 % DMSO 
solution in H2O. 
 
 
Figure III.5.3-7 Cytotoxicity of compound JMV4630 compared to compound JMV4463. MDA-
MB-231 cells were incubated at 10 μM concentration for five days. The control is 1% DMSO 
solution in H2O.  
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Encouraged by our results with compound JMV4463 we synthesized and 
tested for cytotoxicity the compound JMV4630 in which the (AMPA)4 moiety was 
substituted by (DBT)4. To our surprise even though this compound was able to inhibit 
the isolated CD (Figure III.5.2-1) it was non toxic in vitro after five days of incubation 
at 10-5 M (Figure III.5.3-7). A possible explanation is that this compound is not 
internalized in the same way as the JMV4463. We performed a series of 
internalization test that will be discussed in the next chapter. 
 
III.5.4. Internalization essays of fluorescently labelled CD inhibitors 
 
Confocal laser scanning microscopy (CLSM) (see section I.2.3) analyses were 
also performed on living cells (MDA-MB-231) to assess the internalization and 
intracellular distribution of the fluorescently labelled vectorized CD inhibitors. Cells 
were incubated with a membrane marker (lipid raft labelling). To gain more insight 
into the internalization, co-staining was performed with other fluorescent markers for 
subcellular components such as the nucleus and the lysosomes. These experiments 
were associated with a kinetic study of the bioconjugates internalization. First studied 
compound was JMV4626 which is the fluorescently labelled analogue of the toxic 
JMV4463. Co-staining with a membrane marker (lipid-raft labelling) indicated that this 
compound was not held in the lipid membrane after three hours and was internalized 
into the cell (Figure III.5.4-1 A). It was mainly localized in vesicular like compartments 
probably the endosomes or the lysosome. At the 16th hour the compound was co-
localized with the lysosome marker (Figure III.5.4-1 B). We performed a similar 
experiment with compound JMV4631 that was devoid of an oligoAMPA CPNP 
moiety. This compound was not internalized at all after 16 hours (Figure III.5.4-2). 
This fact proves the importance of the AMPA tetramer for the internalization of the 
pepstatine moiety. The extracellular localization of the FITC-conjugated compound 
(JMV4631) could explain the nontoxicity of its acetylated analogue (JMV4567)  
 
Next we performed tests with compound JMV4629 (FITC-β-Ala-r-O2Oc-peps-
DBT4-NH2). The compound was not co-stained with the membrane marker at 3 or 24 
hours and was very well internalized in the cell in vesicular compartments. At the 16th 
hour the compound was co-localized with the lysosome marker.  
 
The results of the CLSM with compounds JMV4629 and JMV4626 suggested 
the ability of the CPNP (DBT)4 and (AMPA)4 to deliver biologically relevant cargos 
(pepstatine) inside the cells. In the same time the pepstatine vectorized by these two 
classes of CPNP showed different biological activities. High toxicity was observed 
when vectorized by (AMPA)4 and no toxicity at all when vectorized by (DBT)4. The 
possible reasons for these differences will be discussed in the next chapter 
 
III.5.5 Discussion 
 
We have tested a series of pepstatine analogues linked to a CPP or CPNP at 
their C-terminus for their ability to inhibit the Cathepsin D and for their cytotoxicity in 
vitro. We obtained very encouraging results with compounds composed of pepstatine 
moiety linked to an AMPA tetramer at their C-terminus and cationic solubilizing 
moiety at their N-terminus. Our lead compound JMV4463 was able to inhibit the 
isolated CD and its fluorescent analogue 4626 was able to penetrate into MDA-MB-
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231 cells. Analogues of this compound with modified pepstatine moiety were worst 
inhibitors of the CD and showed less or no toxicity. Compound JMV4622 devoid of 
polyethylene glycol linker showed similar cytotoxicity thus probably this linker is not 
crucial for the activity. Also compounds with different charged aminoacid (D-Lys 
instead of D-Arg) showed similar activity while compound with D-Asp instead of D-
Arg showed no toxicity. 
 
 
Figure III.5.4-1 Confocal microscopy images of living MDA-MB-231 breast cancer cells 
incubated with compound JMV4626. Images are representative of at least 3 independent 
experiments. A) Distribution of JMV4626 after 3 and 16 hours of incubation at 37°C. Cells 
were incubated at 10-5 M B) Co-localization of JMV4626 with the lysosome marker at 16 h at 
37°C.  
 
 
 
Figure III.5.4-2 Confocal microscopy images of living MDA-MB-231 breast cancer cells 
incubated with compound JMV4631. Images are representative of at least 3 independent 
experiments and represent the distribution of JMV4631 after 16 hours of incubation at 10-5 M.  
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Figure III.5.4-3 Confocal microscopy images of living MDA-MB-231 breast cancer cells 
incubated with compound JMV4629. Images are representative of at least 3 independent 
experiments. A) Distribution of JMV4629 after 3 and 24 hours of incubation at 37°C. Cells 
were incubated at 10-5 M B) Co-localization of JMV4629 with the lysosome marker after 16 h 
at 37°C. 
 
Probably a charged lysine or arginine residue is important mostly for the solubility of 
the compounds in aqueous media. Similar studies were performed with the DBT 
analogue of JMV4463 – JMV4630. JMV4630 is a potent inhibitor of the CD and its 
fluorescently labelled analogue was well internalized into the cells but it did not 
exhibit any cytotoxicity in vitro. One of the possible explanations is that JMV4463 
toxicity is not related with CD inhibition but another yet unknown target. Another 
explanation is that compound JMV4630 is internalized in a different way so it is 
unable to interact with the CD. It is very important to understand the exact 
mechanism of action of JMV4463 so we could design even more powerful 
compounds. If this compound is truly toxic via its interaction with CD we could 
perform very important studies on the CD implication in cancer growth and 
development. The good results with JMV4463 encouraged us to perform tests in 
vivo. Tests for anti-cancer activity on mice are currently under way. 
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IV. CONCLUSION AND PERSPECTIVES 
 
IV.1 Structural studies of DBT and AMPA oligomers 
The protons of oligomers Ac-(DBT)n-NH2 n=[1-6] were assigned using a 
combination of 2D NOESY, 2D ROESY, 2D COSY and 2D TOCSY experiments. 
Numerous NOE interactions were detected in the Ac-(DBT)6-NH2 molecule by 2D 
NOESY experiments. The volumes of these interactions were integrated and 
converted to distance restrictions. The immediate perspective for this project is to use 
these distance restrictions for the determination of the DBT hexamer structure in 
solution by molecular modelization studies. Unfortunately for the time being the 
crystallization essays have not produced crystals suitable for X-Ray studies. Powder 
diffraction experiments are currently performed with compounds: -(Lys-DBT)3-, -
(DBT)3- and Ac-(DBT)6-NH2. 
 
If the structure of the DBT oligomers is determined we could use this moiety 
as a building block for biomimetics with correctly positioned crucial functions on a 
target-by-target basis. Such compounds could be used to disturb specific protein-
protein interactions. Determination of the secondary structure of the DBT oligomers 
could give us also some indications for the internalization mechanism of these 
biomimetics. 
 
IV.2 DBT and AMPA oligomers as cell penetrating non-
peptides 
DBT and AMPA tetramers have been described as a new class of cell 
penetrating non-peptides. These short oligomers share a lot of features – their small 
size, hydrophobic non-cationic nature and high intracellular uptake. Both compounds 
(DBT)4 and (AMPA)4 possess four aromatic unites that are probably an important 
feature for their internalization. Also both compounds are delivered to the lysosome 
via endocytosis. These CPNP could be used to deliver drugs for the treatment of 
cancer, lysosomal storage disease and Alzheimer‘s disease. 
For the time being we have shown the ability of these compounds to deliver 
fluorescent dies and small peptides like the pepstatine inside the cell. Another 
interesting perspective is to synthesize bioconjugates between these CPNPs and 
drugs for the treatment of Alzheimer‘s disease as one of the enzyme implicated in the 
production of the amyloid peptide is mainly localized in the endosomes and the 
lysosomes.  
Another important task is to better understand the internalization mechanism 
of these new CPNP so we could synthesize compounds with even higher intracellular 
uptake and well defined intracellular localization.  
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IV.3 A straightforward approach for cellular-uptake 
quantification of CPPs and CPNPs 
We have described a straightforward and efficient method for the 
quantification of cell-penetrating compounds internalization. The originality of the 
methodology relies first on the use of the combination of HCCA as a UV-light-
absorbing tag and the neutral HCCE matrix, which enabled the very sensitive 
detection of the compounds of interest by mass spectrometry even in complex 
biological medium. We have used this methodology to straightforward evaluate the 
intracellular concentration of two well known CPP – (Arg)8, penetratine and our 
CPNP (DBT)4. 
One of the perspectives ahead us is to straightforward evaluate the 
intracellular concentration of our CPNP (AMPA)4. Another direction for research is to 
design a new tag composed of HCCA connected to a specific peptide sequence that 
could be cleaved only inside the cell. The HCCA moiety will be connected to CPP or 
CPNP via this cleavable linker. Thus we could make a difference between the 
internalized CPP/CPNP and the CPP/CPNP that is attached to the membrane 
IV.4 Vectorization of pepstatine 
We have designed a vectorized inhibitor of the Cathepsin D enzyme 
(compound JMV4463) by the conjugation of the pepstatine moiety to (AMPA)4 and a 
solubilizing moiety. This compound was still able to inhibit the isolated Cathepsin D 
and showed considerable toxicity in vitro.  
An important quantity of JMV4463 has been synthesized and we are currently  
performing in-vivo test for anti-cancer activity on mice. JMV4463 is a potential anti-
breast cancer drug. Very important for this project is to prove that our compound is 
toxic because of its interaction with CD and not some other target inside the cell. If 
this compound is truly toxic via its interaction with CD we could perform very 
important studies in vitro and in vivo on the CD implication on cancer growth and 
development 
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V.   MATERIALS AND METHODS 
 
V.1 Materials 
 
All amino acid derivatives were purchased from Iris Biotech. The other 
chemicals were purchased from: commercial suppliers, Iris Biotech, Senn Chemicals, 
Merck, Carlo Erba, Fluka, Riedel-de Haën, Sigma Aldrich, Acros Organics, 
FluoroChem and VWR Prolabo. The 2-chlorotrityl chloride resin (100-200 Mesh, 1.55 
mmol/g Cl/g resin) was purchased from Iris Biotech, stored at 4°C and dried under 
vacuum at least 24 hours before use. Fmoc Rink amide polystyrene resin (100-200 
mesh, 0.46 mmol/g) was purchased from SENN chemicals, Gentilly, France. 
Fluorescein isothiocyanate (FITC) was purchased from Sigma-Aldrich, Lyon, France. 
The Solvents used for HPLC and LC/MS were of HPLC grade. All final compounds 
were purified by reversed-phase HPLC and the purity assessed by analytical 
reversed-phase HPLC was found superior to 98 %. 
 
V.2 Characterization of the compounds  
 
Analysis of the compounds. HPLC: The samples were prepared in 
acetonitrile/water (50/50 v/v) mixture, containing 0.1% TFA. Samples that were not 
soluble in this mixture were prepared in DMSO. The HPLC system consisted of a 
Beckman 32 Karat System. All the analyses were carried out using a RP C18 VWR 
chromolith column, 50 mm x 3.9 mm. A flow rate of 5 mL/min and a gradient of (0–
100)% B over 3 min were used. Eluent A: water/0.1% TFA; eluent B: 
acetonitrile/0.1% TFA. The detection was performed both at 214 nm and 254 nm. 
 
LC/MS Analysis. Samples were prepared in acetonitrile/water (50/50 v/v) mixture, 
containing 0.1% TFA. The samples that were not soluble in this mixture were 
prepared in DMSO. The LC/MS system consisted of a Waters Alliance 2690 HPLC, 
coupled to a Waters-Micromass ZQ spectrometer (electrospray ionization mode, 
ESI+). All the analyses were carried out using a RP C18 monolithic Onyx 
Phenomenex 25 x 4.6 mm column. A flow rate of 3 mL/min and a gradient of (0–3 
100)% B over 3 min were used. Eluent A: water/0.1% formic acid; eluent B: 
acetonitrile/0.1% formic acid. Positive ion electrospray mass spectra were acquired 
at a solvent flow rate of 100–500 μL/min. Nitrogen was used for both the nebulizing 
and drying gas. The data were obtained in a scan mode in 0.1s intervals; 10 scans 
were summed up to get the final spectrum.  
 
The yield and the purity after HPLC purification, HPLC retention time, calculated 
monoisotopic mass and detected mass of the compounds reported in the manuscript 
are presented  in table V.4  
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V.3 Liquid phase synthesis 
 
Synthesis of Fmoc-DBT-OH 
  
 Section III.1 
 
Synthesis of Boc-D-Cys-OH 
 
 
 
Compound Mw (g.mol-1) Equivalent Mmol Mass/volume 
H-D-Cys-OH.HCl 159 1 125,786 20,00gr 
Boc2O* 218 1.5 188,679 41,14ml 
Triethylamine(TEA)** 101 2 251,572 34,90ml 
 
*- d Boc2O=1,01 
**- d TEA =0.728  
 
H-D-Cys-OH.HCl (20,000 gr, 125,786 mmol) was dissolved in mixture of 150ml of 
H2O and 150 ml dioxan in a flask. The TEA (34,90ml, 251,572 mmol) was added and 
the reaction mixture was cooled down to 0°C with an ice bath. Boc2O (41,14ml, 
188,679 mmol) was dissolved in 50ml of dioxan and then was added dropwise. The 
reaction mixture was stirred at room temperature for four hours. Then 200 ml of the 
reaction mixture were evaporated under reduced pressure. The remaining solution 
was acidified to pH 3 by 1M solution of KHSO4 and the aqueous phase was extracted 
three times with ethyl acetate. The organic phases were collected, washed with brine 
and dried over MgSO4. Then the ethyl acetate was removed under reduced pressure 
to obtain 33,105 gr of Boc-D-Cys-OH as transparent oil. The weight of the obtained 
product was more than the calculated theoretical yield because of the presence of 
Boc-Cys(Boc)-OH.  
 
Characterization:  
 
HPLC: Rt = 1,10 mn ; MS (ESI): m/z 222 [(M+H)+] ; C8H15O4NS. 
 
Synthesis (S)-2-(tert-butoxycarbonylamino)-3-(2-nitrophenylthio)propanoic acid 
(A) 
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Compound Mw (g.mol-1) Equivalent Mmol Mass 
Boc-D-Cys-OH* 221 1 125,79 33,11gr* 
NaHCO3 84 3 377,39 31,67gr 
2-fluoronitrobenzen** 140 1 125,79 12,58ml 
*Mixture of Boc-D-Cys-OH and Boc-D-Cys(Boc)-OH 
** d2-fluoronitrobenzen =1.4 
 
 
2-fluoronitrobenzen (12,58 ml, 125,79 mmol), Boc-D-Cys-OH (33,11 gr, 125,79 
mmol) and NaHCO3 (31,67 gr, 377,37mmol ) were dissolved in a mixture of 300 ml 
H2O and 300 ml EtOH . The reaction mixture was refluxed for 12 hours. Then we 
evaporated 400ml of the solvent and the resulting reaction mixture was washed 2 
times by EtOEt in separatory funnel. The aqueous phase was acidified to pH 3 by 1M 
solution of KHSO4 and extracted three times with ethyl acetate. The organic phases 
were collected, washed with brine and dried over MgSO4. The ethyl acetate was 
removed under reduced pressure to obtain 44,11 gr of (A) as an yellow oil. 
 
Expected mass of (A) =43.20 gr 
Obtained mass=44,11 gr (residual solvent or salts) 
 
Yield for the first two reaction – quantitative of chromatography pure product 
 
Characterization:  
 
HPLC: Rt = 1,56 mn ; MS(ESI): m/z 343.0 [(M+H)+], 685.5 [(2M+H)+] ; []D
20 = -75 (c 
1.0, CH3OH).  
RMN 1H (CDCl3): conformer I (37%): 1.42 (s, 9H, (CH3)3C), 3.30 (m(br), 1H, S-HCH), 
3.62 (m(br), 1H, S-HCH), 4.57 (m(br), 1H, NH-CH-CO), 7.05 (br, 1H, NH), 7.34 (d, J 
= 8.0 Hz, 1H, Ar-H), 7.60 (s, 1H, Ar-H), 8.21 (d, J = 8.0 Hz, 1H, Ar-H). conformer II 
(63%): 1.46 (s, 9H, (CH3)3C), 3.42 (m(br), 1H, S-HCH), 3.62 (m(br), 1H, S-HCH), 
4.69 (m(br), 1H, NH-CH-CO), 5.46 (d, J = 6.5 Hz, 1H, NH), 7.32 (d, J = 8.0 Hz, 1H, 
Ar-H), 7.60 (s, 1H, Ar-H), 8.17 (d, J = 8.0 Hz, 1H, Ar-H).  
RMN 13C (CDCl3): conformer I : 28.50 ((CH3)3C), 36.25 (S-CH2), 53.51 (N-CH-CO), 
81.16 ((CH3)3C), 125.74 (Ar-CH), 126.63 (Ar-CH), 127.44 (Ar-CH), 134.08 (Ar-CH), 
136.41 (Ar-C), 147.12 (Ar-C), 157.10 (N-CO-O), 174.09 (COOH), conformer II : 28.67 
((CH3)3C), 35.28 (S-CH2), 52.85 (N-CH-CO), 81.34 ((CH3)3C), 125.93 (Ar-CH), 
126.44 (Ar-CH), 128.15 (Ar-CH), 134.08 (Ar-CH), 135.73 (Ar-C), 147.50 (Ar-C), 
155.84 (N-CO-O), 174.54 (COOH). 
 
Synthesis (S)-3-(2-aminophenylthio)-2-(tert-butoxycarbonylamino)propanoic 
acid (B) 
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Compound Mw (g.mol-1) Equivalent Mmol Mass 
(A)  1 125,786 44,11 gr 
Fe (Powder)  1 mass eq.  44,11gr 
NH4
+Cl-  0,1 mass eq.  4,411gr 
 
 
44,11 gr (125,79 mmol) of (A) were dissolved in a mixture of 300 ml of EtOH and 150 
ml of H2O in a flask and then the Fe powder (44,11 gr) and ammonium chloride (4,41 
gr)  were added. The reaction mixture was refluxed on stirring by mechanical 
agitation for 4 hours. Then the solution was filtered through celite, the celite was 
washed two times with boiling EtOH and the organic phases were collected. We 
evaporated 400 ml of the reaction mixture and added around 150 ml of H2O to it. The 
aqueous phase was extracted 5 times with ethyl acetate. The collected organic 
phases were washed with brine, dried over MgSO4, and the ethyl acetate was 
removed under reduced pressure to obtain 33,12 of (B) as a brown powder. 
 
Expected weight 39,25 gr 
Obtained weight 33,12 gr 
 
Yield=84.34% of chromatographically pure  
 
Characterization:  
 
HPLC: Rt = 1,3 mn ; MS (ESI): m/z 312.9 [(M+H)+], 621.3 [(2M+H)+] ; []D
20 = +43 (c 
1.0, CH3OH) ; C14H20O4N2S. 
RMN 1H (CDCl3): 1.26 (s, 9H, (CH3)3C), 3.06 (m(br), 1H, S-HCH), 3.14 (m(br), 1H, S-
HCH), 4.28 (m(br), 1H, NH-CH-CO), 5.46 (br, 2H, NH2), 5.79 (br, 1H, NH), 6.60 (t, J1 
= J2 = 7.4 Hz, 1H, Ar-H), 6.66 (d, J = 7.4 Hz, 1H, Ar-H), 7.01 (t, J1 = J2 = 7.4 Hz, 1H, 
Ar-H), 7.31 (d, J = 7.4 Hz, 1H, Ar-H).  
RMN 13C (CDCl3): 28.70 ((CH3)3C), 38.28 (S-CH2), 55.18 (N-CH-CO), 80.46 
((CH3)3C), 116.57 (Ar-CH), 118.65 (Ar-C), 120.13 (Ar-CH), 130.50 (Ar-CH), 136.89 
(Ar-CH), 147.86 (Ar-C), 156.12 (N-CO-O), 176.55 (COOH). 
 
Synthesis of (S)-tert-butyl 4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-
ylcarbamate (C) 
 
 
Compound Mw (g.mol-1) Equivalent Mmol Mass 
(B) 312 1 106.10 33,10gr 
BOP 442 1 106.10 46.90gr 
NaHCO3 121.7 5 530,50 64,56gr 
 
 
33,10 gr (106,10 mmol) of (B) were dissolved in 600ml of DMF and then the NaHCO3 
(64,56 gr, 530,50 mmol) and the BOP (46,56 gr, 106,10 mmol) were added. The 
reaction mixture was stirred for 24 hours at room temperature. After that the DMF 
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was evaporated under reduced pressure and the obtained oil was dissolved in ethyl 
acetate. The organic phase was subsequently washed 3 times by saturated solution 
of NaHCO3 and brine and dried over MgSO4. The ethyl acetate was removed under 
reduced pressure to obtain the crude (C) as a brown powder that was further purified 
by flash chromatography (AcOEt/Hex : 5/5) to obtain 18.31gr of white powder. 
 
Expected weight=31,19gr 
Obtained weight=18.31gr 
 
Yield=58,70% of chromatography pure product 
 
Characterization:  
 
HPLC: Rt= 1,5 mn ; MS(ESI): m/z 295.0 [(M+H)+], 611.1 [(2M+Na)+] ; []D
20 = +274 (c 
1.0, CH3OH). 
RMN 1H (CDCl3): 1.33 (s, 9H, (CH3)3C), 2.28 (t, J1 = J2 = 11.4 Hz, 1H, S-HCH), 3.75 
(dd, J = 6.6 Hz et 11.4 Hz, 1H, S-HCH), 4.41 (m, 1H, NH-CH-CO), 5.61 (d, J = 7.8 
Hz, 1H, NHBoc), 7.06 (d, J = 6.8 Hz, 1H, Ar-H), 7.10 (t, J1 = J2 = 6.8 Hz, 1H, Ar-H), 
7.28 (t, J1 = J2 = 6.8 Hz, 1H, Ar-H), 7.53 (d, J = 6.8 Hz, 1H, Ar-H), 8.45 (s, 1H, NH). 
RMN 13C (CDCl3): 28.71 ((CH3)3C), 39.66 (S-CH2), 50.80 (N-CH-CO), 80.60 
((CH3)3C), 124.17 (Ar-CH), 127.14 (Ar-C), 127.65 (Ar-CH), 130.49 (Ar-CH), 135.79 
(Ar-CH), 140.44 (Ar-C), 155.02 (N-CO-O), 172.88 (CONH). 
 
 
Synthesis of (S)-tert-butyl 2-(3-(tert-butoxycarbonylamino)-4-oxo-3,4-
dihydrobenzo[b][1,4]thiazepin-5(2H)-yl)acetate (D) 
 
 
 
Compound Mw (g.mol-1) Equivalent Mmol Mass 
(C) 294 1 62.28 18.31gr 
NaH 24 2 124,56 2,99gr 
BrCH2COOtBu* 195 1,1 68.51 10.11ml 
*dBrCH2COOtBu=1.321 
 
18,31 gr (62,28 Mmol) of (C) were dissolved in 150 ml of anhydrous THF in a flask 
under inert argon and after cooling to 0°C with ice bath, NaH (2,99 gr) was added 
slowly for about 20 minutes. When the release of H2 was over a solution of 
BrCH2COOtBu (10,11 ml) in 40ml of anhydrous THF was added drop wise.  The flask 
was closed under inert argon and the reaction mixture was stirred for 4 hours. After 
the completion of the reaction (HPLC controlled) 1M solution KHSO4 was added drop 
wise to neutralize the residual NaH. After that 150 ml of 1M solution of KHSO4 were 
added and the obtain mixture was extracted three times with ethyl acetate. The 
organic phases were collected, washed with brine and dried over MgSO4. The ethyl 
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acetate was removed under reduced pressure to obtain 25.71gr of (D) as transparent 
oil.  
 
Expected weight=25.55gr 
Obtained weight=25.71gr 
 
Yield = quantitaitve of chromatography pure product 
 
Characterization:  
 
HPLC: Rt = 1,97 mn ; MS(ESI): m/z 409.0 [(M+H)+] ; C20H28O5N2S 
 
Synthesis of (S)-2-(3-amino-4-oxo-3,4-dihydrobenzo[b][1,4]thiazepin-5(2H)-
yl)acetic acid (E) 
 
 
25.71gr (68,75 mmol) of (D) were dissolved in 150ml of 98% solution of TFA and the 
reaction mixture was stirred for 4 hours. The TFA was evaporated under reduced 
pressure. Five co-evaporations with 150 ml of EtOEt each were performed to take 
away the residual non-evaporated TFA. Then (E) was precipitated in EtOEt, filtered, 
washed many times with EtOEt and dried under reduced pressure to obtain 23.10 gr.  
 
Expected weight=22.88gr 
Obtained weight=23.10gr 
 
Yield = quantitative of chromatography pure product 
 
Characterization:  
 
HPLC: Rt=0,87 mn ; MS(ESI): m/z 253.0 [(M+H)+] 
 
Synthesis of (3-S)[amino]-5-(carboxylmethyl)-2,3-dihydro-1,5-benzothiazepin-
4(5H)-one Fmoc-DBT-OH (F) 
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Compound Mw (g.mol-1) Eq Mmol Mass 
FmocOSu 366 1.1 68.75 25,16 gr 
(E) 336 1 62.5 22.88 gr 
Na2CO3 106 1.5 93,75 9.94 gr 
 
 
 (E)  (25,16 gr, 62,75 mmol) and Na2CO3 (9,94 gr, 93,75 mmol) were dissolved in a 
mixture of 300 ml H2O and 300 ml dioxan. The reaction mixture was cooled down to 
0°C and FmocOSu (25,16 gr, 68,75 mmol) was added drop wise dissolved in 100ml 
of dioxan. The reaction mixture was stirred for 12 hours at room temperature. After 
the completion of the reaction (controlled by HPLC) 400 ml of the solvent were 
evaporated. The aqueous phase was washed 2 times with EtOEt, acidified to pH 3 by 
KHSO4 and extracted 3 times with ethyl acetate. The organic phases were collected, 
washed with brine and dried over MgSO4. The ethyl acetate was removed under 
reduced pressure to obtain 29,10 gr of Fmoc-DBT-OH as white powder.  
 
Expected weight=29,75 
Obtained weight=29,10 
 
Yield = 97,81% of chromatography pure product 
 
Characterization:  
 
HPLC: Rt = 1,88 mn ; MS(ESI): m/z 474.9 [(M+H)+] ; C26H22O5N2S. 
RMN 1H (CDCl3): 2.90 (t, J1 = J2 = 11.1 Hz, 1H, S-HCH), 3.45 (dd, J = 6.8 Hz et 11.1 
Hz, 1H, S-HCH), 3.80 (t, J1 = J2 = 7.6 Hz, 1H, CO-O-CH2-CH), 4.15 (d, J = 7.6 Hz, 
2H, CO-O-CH2-CH), 4.30 (d, J = 17.6 Hz, 1H, N-HCH), 4.50 (m, 1H, NH-CH-CO), 
4.90 (d, J = 17.6 Hz, 1H, N-HCH), 5.85 (d, J = 7.8 Hz, 1H, NHFmoc), 7.25 (d, J = 7.6 
Hz, 2H, Ar-H), 7.35 (d, J = 7.6 Hz, 2H, Ar-H), 7.40 (d, J = 7.6 Hz, 2H, Ar-H), 7.45 (d, J 
= 7.6 Hz, 1H, Ar-H), 7.55 (m, 2H, Ar-H), 7.65 (d, J = 7.6 Hz, 1H, Ar-H), 7.75 (d, J = 
7.6 Hz, 2H, Ar-H), 8.90 (br, 1H,  CO2H). 
 
Synthesis of 2-aminomethyl-phenyl-acetic acid (Fmoc-AMPA-OH) 
 
Section III.1 
 
 
 
Compound Mw (g.mol-1) Eq mmol Mass 
FmocOSu 337 1,1 27,30 9.20 gr 
AMPA 201.65 1 24.80 5 gr 
Na2CO3 106 1.5 37.20 3.94 gr 
 
AMPA (5 gr, 24,80 mmol) was dissolved with Na2CO3 (3,94 gr, 37,20) in a mixture of 
200 ml H2O and 200 ml dioxan. The solution was cooled down to 0°C and FmocOSu 
(9,20 gr, 27,30 mmol) was added drop wise dissolved in 100ml of dioxan. The 
reaction mixture was stirred for 12 hours at room temperature. After the completion of 
the reaction (controlled by HPLC) about 300ml of the solvent were evaporated. The 
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aqueous phase was washed 2 times with EtOEt, acidified to pH 3 with KHSO4 and 
extracted 3 times with ethyl acetate. The organic phases were collected, washed with 
brine and dried over MgSO4. The ethyl acetate was removed under reduced pressure 
to obtain 8.81 gr of Fmoc-AMPA-OH as white powder.  
 
Expected weight=9.60 
Obtained weight=8.81 
 
Yield = 91,77 % of chromatography pure product 
 
Characterization:  
 
HPLC: Rt = 1,70 mn ; MS(ESI): m/z 388 [(M+H)+] ; C8H15O4NS. 
 
 V.4 SPPS 
 
Anchoring on Rink amide-PS resin 
 
Sections: III.2.1, III.3.1.1, III.3.1.2, III.5.1 
 
Fmoc-Rink amide resin was conditioned for 30 minutes in DCM and submitted to the 
standard deportation cycle, using two times DMF/pip 80/20 v/v solution for 30 
minutes. After washing steps, the first constrained dipeptide mimetic (Fmoc-LBT-
OH/Fmoc-DBT-OH or Fmoc-AMPA-OH) motif or Fmoc protected amino acid was 
loaded onto the resin through a standard coupling cycle, using HBTU (3 eq.) as a 
coupling agent and DIEA (3 eq.) as a base. 
 
Anchoring on 2-chlorotrityl chloride PS resin 
 
Sections: III.2.1 
 
The anchoring was carried out manually in a plastic syringe equipped with frit. 2 
grams of 2-chlorotrityl chloride PS resin with theoretical charge of 1.55 mmol/gr 
(about 3,10 mMol) was conditioned for 30 minutes with anhydrous DCM. After that 
the resin was incubated with 3,67gr (7,75 mmol) of Fmoc-DBT-OH dissolved in 15ml 
of anhydrous DMF and 2,66ml (7,75 mmol) of DIEA and stirred mechanically 
overnight. By UV titration after the deprotection of the Fmoc group we determined a 
charge of 0.77 mmol/gr on the resin after the anchoring of the first DBT moiety. 
 
Coupling steps 
 
Sections: III.2.1, III.3.1.1, III.3.1.2, III.5.1 
 
The Coupling reaction was carried out manually in plastic syringes equipped with 
frits. HBTU (3 eq) as a coupling agent, DIEA (3 eq) as a base and Fmoc protected 
moieties (D/L natural aminoacids, D/L BT, AMPA, Ahx, O2Oc or β-Ala) or isovaleric 
acid (3eq according to resin loading) were solubilized in DMF and added to the resin. 
The reaction was stirred for 3 hours at room temperature. The reaction was 
monitored by the standard TNBS test.76 
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Deprotection step 
 
Sections: III.2.1, III.3.1.1, III.3.1.2, III.5.1 
 
Fmoc deprotection was carried out using DMF/piperidine 80/20 v/v solution two times 
for 30 minutes. Only in the case of deprotection of an AMPA moiety was used 
DMF/Piperidine/DBU 46/2/2 v/v/v solution two times for 45 minutes. This treatment 
allowed us to avoid incomplete deprotections that were observed with the standard 
DMF/Piperidine solution. 
 
Washing steps  
 
Sections: III.2.1, III.3.1.1, III.3.1.2, III.5.1 
 
Washing steps were performed after each coupling and deprotection steps: one time 
methanol, one time DCM, 3 times DMF and 3 times DCM. 
 
FITC coupling  
 
Sections: III.3.1.1, III.3.1.2, III.5.1  
 
FITC reaction was carried out manually in plastic syringes equipped with frits. 1.5 eq. 
of FITC and 3 eq. of DIEA (according to resin loading) were solubilized in DMF and 
added to the resin. The reaction was stirred for 2 hours at room temperature.  
 
Acetylation 
 
Acetylation was carried manually in plastic syringes equipped with frits using 
DCM/Ac2O solution 2 times for 15 minutes. 
 
Cleavage of Rink amide PS resin  
 
Oligomers were cleaved from resin for 4 hours by 99% trifluoroacetic acid. After 
removal of the resin by filtration, the resin was washed multiple times with DCM. The 
DCM and trifluoroacetic acid filtrates were concentrated under reduced pressure. 
Compounds were precipitated by addition of diethyl ether and filtrated. They were 
dissolved in acetonitrile/water 50/50 solution containing 0.1% TFA and freeze dried. 
 
Cleavage of 2-chlorotrityl chloride PS resin  
 
Sections: III.2.1 
 
In the case of DBT homo-oligomers the peptides were cleaved from the resin in the 
same reaction conditions as for the RA PS resin.  
 
(DBT-Lys)n hetero-oligomers  were cleaved from the resin for 3 hours by TFE/DCM 
3/7 v/v solution. After removal of the resin by filtration, the resin was washed multiple 
times with DCM. The DCM and DCM/TFE filtrates were concentrated under reduced 
pressure. The products were precipitated by addition of diethyl ether and filtrated. 
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They were dissolved in acetonitrile/water 50/50 solution containing 0.1% TFA and 
freeze dried. 
 
Microwave assisted solid phase peptide synthesis  
 
Section: III.4.1 
 
Residue coupling conditions: Fmoc-amino acids or Fmoc-DBT-OH (0.5 mmol, 0.2 M) 
in 2.5 mL of DMF were used for the stepwise synthesis following the solid phase 
peptide synthesis procedure, using a solution of HBTU in DMF (0.5 mmol, 0.5 M, 1 
mL), and a solution of DIEA in DMF (1 mmol, 2M, 0.5 mL) under N2 for 5 min at 23W 
and 70°C. These conditions were also used to couple Boc-HCCA and Boc HCCA(D) 
on the amino function of Ahx residue. 
 
Fmoc deprotection: removal of the Fmoc protecting group was carried out using 20% 
piperidine in DMF (7 mL) at 40W for 30s at 75°C and then 20% piperidine in DMF (7 
mL) at 35W for 3 min at 70°C. These conditions were also used to remove the Fmoc 
protecting group from Fmoc-Rink amide polystyrene resin (100-200 mesh, 0.46 
mmol/g).  
 
Cleavage and deprotection of amino-acid side chains: After performing all the 
coupling/deprotection cycles, the peptidyl or DBT-containing resin was cleaved with a 
TFA/TIS/H2O 95/2.5/2.5 v/v/v) solution, for 120 minutes at room temperature, under 
gentle stirring. Resin was filtered, washed with cleavage solution and the filtrate was 
concentrated in vacuum. The residue was washed with diethyl ether and then dried 
at room temperature. 
 
Purification of the compounds  
 
All the compounds were purified by preparative HPLC (Waters 4000 apparatus) 
carried out on a C18 reversed-phase column (C18 Deltapak column, 100 mm x 40 
mm, 15μm, 100Å) at a flow rate of 50 mL/min of a mixture of H2O + 0.1% TFA and 
CH3CN + 0.1% TFA in gradient mode with UV detection at 214 nm or 254 nm.  
 
The yield and the purity after HPLC purification, HPLC retention time, calculated 
monoisotopic mass and detected mass of the compounds are reported in table V.4 
 
Table V.4 List of the synthesized compounds. Between brackets and in bold in the Mass 
spectrometry section are reported the expected masses of the compounds 
Compound Sequence MS: Ion detected 
(expected mass)  
Rt 
(min) 
Yield 
Section III.2.1.1  
JMV4279 Ac-DBT-NH2 [M+H]
+- 293.1(293.07) 1.15 60% 
JMV4280 Ac-(DBT)2-NH2 [M+H]
+- 528.2 (527.1) 1.22 50% 
JMV4281 Ac-(DBT)3-NH2 [M+H]
+- 762.2(761.15) 1.35 45% 
JMV4169 Ac-(DBT)4-NH2 [M+H]
+-996.2 , [M+2H]2+-
498,6 (995,2) 
1.51 35% 
JMV4170 Ac-(DBT)5-NH2 [M+H]
+-1230.2 , 
[M+2H]2+-615.6 (1229.2) 
1.61 25% 
JMV4172 Ac-(DBT)6-NH2 [M+H]
+-1464.4 , 1.73 15% 
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[M+2H]2+-732.6 (1463.3) 
JMV4282 Ac-(DBT)7-NH2 [M+2H]
2+- 849.9 (1697.3) 1.88 13% 
JMV4283 Ac-(DBT)8-NH2 [M+2H]
2+- 966.7(1931.4) 1.91 11% 
JMV4286 Ac-DBT-LBT-DBT-LBT-NH2 [M+H]
+-996.2 , [M+2H]2+-
498,6 (995,2) 
1.41 34% 
JMV4176 Ac-(AMPA)4-NH2 [M+H]
+-648.4, [M+2H]2+-
324.8, [M+Na]+-670.3 
(647.4) 
1.30 52% 
JMV4288 Ac-(AMPA)5-NH2 [M+2H]
2+-398.2 (794.35) 1.90 25% 
JMV4086 Z(Br)-(DBT)5-NH2 [M+H]
+-1400,1 , 
[M+2H]2+-700,7(1399,2) 
1.98 20% 
JMV4087 Z(Br)-(DBT)6-NH2 [M+2H]
2+-817,6 (1633.2) 2.04 15% 
Section III.2.1.2  
JMV4675 -DBT-DBT-DBT- [M+H]+-703,2 (702.12) 1.62 17% 
JMV4284 -DBT-DBT-DBT-DBT- [M+H]+- 937.1 (936.16) 1.78 23% 
JMV4678 -(Lys-DBT-Lys-DBT-Lys-
DBT)- 
[M+H]+- 1087.5; 
[M+2H]2+-544.3  (1086.4) 
0.87 27% 
JMV4679 -(Lys-DBT-Lys-DBT-Lys-
DBT-Lys-DBT)- 
[M+2H]2+- 725.4 
[M+3H]3+-483.9 (1448.5) 
0.91 25% 
Section III.3.1.1  
JMV2949 Fl-(DBT)2-NH2 
 
[M+H]+ - 875.00 (874.1) 1.70 35% 
JMV2968 Fl-(DBT)3-NH2 
 
 [M+H]+-1109.1 (1108.2) 1.87 30% 
JMV3229 Fl-(DBT)4-NH2 [M+H]
+-1343.1 [M+2H]2+-
672.1 (1342.2) 
1.80 24% 
JMV4228 Fl-(LBT)4-NH2 [M+H]
+-1343.2, [M+2H]2+-
672.3 (1342.2) 
1.80 25% 
JMV4287 Fl-(DBT-LBT)2-NH2 [M+H]
+-1343.2[M+2H]2+-
672.2 (1342.2) 
1.69 25% 
JMV4236 Fl-(AMPA)3-NH2 [M+H]
+-848.24 , 
[M+2H]2+-424.9 (847.24) 
1.54 46% 
JMV4237 Fl-(AMPA)4-NH2 [M+H]
+- 995.3, [M+2H]2+-
498.2 (994.31) 
1.63 26% 
JMV4497 Fl-O2Oc-r-(AMPA)4-NH2
 [M+H]+-1296.5, [M+2H]2+- 
649.0, [M+3H]3+-433.0 
(1295.5) 
1.34 25% 
Section III.3.1.2 
JMV4568 Fl-Ahx-(DBT)3-Ahx-(Arg)9-
NH2 
[M+4H]4+-686.2, 
[M+5H]5+-549.1, 
[M+6H]6+-457.8, 
[M+7H]7+-392.7 (2739.2) 
1.00 22% 
JMV4569 Fl-Ahx-(DBT)4-Ahx-(Arg) 9-
NH2 
[M+4H]4+-744.66, 
[M+5H]5+-595.86, 
[M+6H]6+-496.92 (2973.2) 
1.09 20% 
- Fl-Ahx-(Arg)8-NH2 [M+4H]
4+-443, [M+5H]5+-
354.6 (1767.9) 
- 30% 
JMV3888 Fl-Ahx-(Arg)9-NH2 [M+4H]
4+-482, [M+5H]5+-
385,8 (1924) 
- 25% 
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Section III.4.1  
JMV4239 HCCA-Ahx-(DBT)4-NH2 [M+H]
+-1238.3, [M+2H]2+-
619.65 (1237.3) 
1.57 40% 
JMV4240 HCCA(D4)-Ahx-(DBT)4-NH2 [M+H]
+-1242.3, [M+2H]2+-
621.6 (1241.3) 
1.57 41% 
JMV4285 Ac-Ahx-(DBT)4-NH2  [M+H]
+-1109.3, 
[M+2H]2+-555.15 (1108.3) 
1.53 45% 
Section III.5.1 
JMV2719 IsoVal-Val2-Sta-Ala-Sta-
(AMPA)4-NH2 
[M+H]+- 1273.6, 
[M+2H]2+-637.3 (1272.7) 
1.67 15% 
JMV4215 IsoVal-(Val)2-γLeu-Ala-
γLeu-(AMPA)4-NH2 
[M+2H]2+-621.4, (1240.8) 1.78 10% 
JMV4216 IsoVal-(Val)2-Sta-Ala-Sta-
(AMPA)3-NH2 
[M+H]+- 1126.7 [M+2H]2+-
563,8 (1125.6) 
1.54 20% 
JMV2729 IsoVal-Val2-Sta-Ala-Sta-
(DBT)4-NH2 
[M+H]+- 1621.5 [M+2H]2+-
811,25 (1620.6) 
1.60 15% 
JMV4461 Ac-D-Lys-O2Oc-(Val)3-Sta-
Ala-Sta-(AMPA)4-NH2 
[M+2H]2+-802.5, 
[M+3H]3+-535.6 (1602.9) 
1.35 35% 
JMV4462 Ac-D-Lys-O2Oc-(Val)3-Sta-
Ala-Sta-(AMPA)5-NH2 
[M+2H]2+- 876.1, 
[M+3H]3+-584.4 (1749.9) 
1.41 25% 
JMV4463 
 
Ac-D-Arg-O2Oc-(Val)3-Sta-
Ala-Sta-(AMPA)4-NH2 
[M+2H]2+- 816.4 
[M+3H]3+-544.6 (1630.9) 
1.37 30% 
JMV4464 Ac-D-Arg-O2Oc-(Val)3-Sta-
Ala-Sta-(AMPA)5-NH2 
[M+2H]2+- 890.1, 
[M+3H]3+-593.8 (1877.9) 
1.42 23% 
JMV4563 Ac-D-Lys-O2Oc-(Val)3-
γLeu-Ala-γLeu-(AMPA)4-
NH2 
[M+H]2+- 786.6, [M+3H]3+-
524.4 (1571) 
1.41 25% 
JMV4564 Ac-D-Arg-O2Oc-(Val)3-
γLeu-Ala-γLeu-(AMPA)4-
NH2 
[M+H]2+- 800.6, [M+3H]3+-
534.1 (1599) 
1.41 26% 
JMV4566 Ac-D-Lys-O2Oc-(Val)3-Sta-
Ala-Sta-NH2 
[M+H]+-1015.7, [M+2H]2+- 
508.4 (1014,6) 
1.07 30% 
JMV4567 Ac-D-Arg-O2Oc-(Val)3-Sta-
Ala-Sta-NH2 
[M+H]+-1043.7, [M+2H]2+- 
522.3 (1042,6) 
1.04 18% 
JMV4625 Ac-D-Asp-O2Oc-(Val)3-Sta-
Ala-Sta-(AMPA)4-NH2 
[M+2H]2+- 795.8, 
[M+3H]3+-531.4 (1589,8) 
1.46 25% 
JMV4626 Fl-betaAla-r-O2Oc-(Val)3-
Sta-Ala-Sta-(AMPA)4-NH2 
[M+2H]2+- 1025.5, 
[M+3H]3+-648.1 (2048,9) 
1.46 26% 
JMV4629 Fl-betaAla-r-O2Oc-(Val)3-
Sta-Ala-Sta-(DBT)4-NH2 
[M+2H]2+- 1199,4, 
[M+3H]3+-800 (2396,8) 
1.55 28% 
JMV4630 Ac-r-O2Oc-(Val)3-Sta-Ala-
Sta-(DBT)4-NH2 
[M+2H]2+- 990,4, 
[M+3H]3+-660,6 (1978,8) 
1.48 25% 
JMV4631 Fl-betaAla-r-O2Oc-(Val)3-
Sta-Ala-Sta-NH2 
[M+2H]2+- 731,3 
(1460,7) 
1.35 30% 
JMV4659 Fl-Ahx-r-O2Oc-(Val)3-Sta-
Ala-Sta-(AMPA)4-NH2 
[M+2H]2+- 1046.5, 
[M+3H]3+-698.2 (2091) 
1.46 22% 
JMV4674 Ac-D-Arg-O2Oc-(Val)3-γ-
Ala-Ala-γ-Ala-(AMPA)4-NH2 
[M+2H]2+- 758,4 (1514,7) 1.62 20% 
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V.5 Biological experiments  
 
Cell Preparation and Treatment with Fluorescently Labelled Oligomers 
  
Sections: III.3.2.1, III.3.2.4.  III.3.3  III.3.4, III.5.4 
 
We used 1 mM stock solutions of compounds dissolved in DMSO that were further 
diluted with serum-free medium to obtain a final concentration of 10-5 M. All 
compounds were protected from light during the experiments, and their fluorescence 
values were regularly verified. Human breast cancer MDA-MB-231 cells were 
maintained in monolayer cultures in Dulbecco‘s modified Eagle‘s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 50 μg/mL gentamycin at 37 °C 
in 5% CO2. One day prior to the experiment, cells were harvested using trypsin in 
phosphate-buffered saline (PBS), centrifuged, and resuspended with culture medium. 
The suspension containing 106 cells/mL was transferred into plastic 24-well plates 
(Becton Dickinson, Le Pont De Claix, France) (200 μL/well) and incubated overnight 
until they reached >90% confluency. On the day of the experiment, the culture 
medium was removed, and the cells were washed once with phenol red-free DMEM. 
Then, 200 μL of DMEM containing 10-5 M of compounds was dispersed on cells. 
Experiments were carried out in triplicate for each compound. To determine the 
amount of compounds assimilated by cells, including membrane-bound fractions, 
cells were washed twice with PBS. To determine the amount of internalized 
compounds, cells were washed with PBS and then treated for 5 min with 30 μL of a 
solution containing 0.5 mg/mL trypsin. After trypsinization, cells were resuspended in 
phenol red-free DMEM and centrifuged for 5 min at 800g. Adherent cells or cell 
pellets were lysed in 200 μL of cell culture lysis reagent (Promega, Charbonnie`res, 
France). After 30 min of incubation at room temperature, 200 μL of distilled water 
was added before analysis on a Gemini XS spectrofluorimeter (Molecular Devices, 
CA, USA), with the excitation wavelength adjusted to 485 nm and emission 
measured at 530 nm. All fluorescence values were normalized according to the 
fluorescence intensity of each compound at 10-5 M in lysis buffer in the presence of 2 
×105 cells. 
 
Kinetics of Internalization  
 
Sections: III.3.2.1 
 
One day before the experiment, 2x106 MDA-MB-231 cells were seeded on plastic 24-
well plates. The cells were then washed with DMEM and incubated for increasing 
times from 1 to 24 h with 10-5 M oligomer at 37°C. At the indicated time, cells were 
treated by trypsin and intracellular fluorescence measured as described above. 
 
Visualization of Fluorescent Oligomers by CLSM 
 
Sections: III.3.2.2, III.3.3, III.3.4, III.3.4.1, III.5.4.2 
 
The day prior to the experiment, MDA-MB-231(MCF7 in section III.3.3) cells were 
seeded onto bottom glass dishes (World Precision Instrument, Stevenage, UK) at a 
density of 106 cells per square centimeter. On the day of the experiment, cells were 
washed once and incubated in 1 mL red-free medium containing fluorescent labelled 
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compounds at a concentration of 10-5 M for 3, 16, and 24 h. Thirty minutes before the 
end of incubation, cells were loaded with Hoechst 33342 (Invitrogen, Cergy Pontoise, 
France) for nuclear staining at a final concentration of 5 μg/mL. For membrane 
labeling, a Vybrant lipid-raft labeling kit (Invitrogen) was used as described by the 
manufacturer. For endosome labeling, 20 min before the end of the experiment, 35 
mg/mL of transferrin (Invitrogen) was added to the culture medium. For lysosome 
labeling, 3 h before the end of the experiment, 50 nM of lysotracker red DND-99 
(Invitrogen) was added to phenol red-free DMEM. Before visualization, cells were 
washed gently with phenol redfree DMEM. Cells were then scanned with a LSM 5 
LIVE confocal laser scanning mi croscope (Carl Zeiss, Le Pecq, France), with a slice 
depth (Z stack) of 0.67 μm. 
 
MTT viability assay 
 
Section: III.3.2.3, III.5.3 
 
Cellular toxicity of the fluorescent agents was examined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay. 
Briefly, 5000 cells were seeded in 96-well plates. Two concentrations (10-5 and 10-6 
M) of compounds were tested for 5 days. Following this incubation, the cells were 
incubated for 4 h with 0.5 mg/mL of MTT in media. After 4 h, the MTT/media solution 
was removed, and the precipitated crystals were dissolved in ethanol/DMSO (1/1). 
The solution absorbance was read at 540 nm. We confirmed this assay to be linear 
and to give comparable results as total DNA quantification by diaminobenzoic acid 
assay.77 
 
Cell Preparation and Treatment with HCCA Labelled Oligomers 
 
Section III.4.1 
 
Cell penetration experiments 
 
Stock solutions of cell penetrating compounds were prepared in DMSO at 1mM and 
then diluted with serum-free medium to obtain a final concentration of 10 µM. Human 
breast cancer MDA-MB-231 cells were cultured at 37°C in Dulbecco‘s modified 
eagle‘s medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and 50 
µg/mL gentamycin. In each 24-well (Becton Dickinson, France), 2.105 cells were 
incubated overnight prior to the experiment. For the experiments, cells were washed 
with phenol red-free DMEM, and then incubated for 3 h with the cell penetrating 
compound solution (200µL, 10 µM, in phenol red-free DMEM). Cells were then 
washed 2 times with 1mL of PBS.  
 
Cell treatment for determination of cellular and membrane-bounded compounds 
 
Cells were lysed with 400 µL of a lysis buffer containing 10 mM Tris and 1 mM EDTA. 
This mixture was incubated for 20 min at room temperature in lysis buffer, and 
lysates were then sonicated for 5 min. Classical buffer containing Triton was not used 
to avoid the PEG-like envelope of cations observed below 1200 Da during MALDI-
TOF MS analysis. 
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Cell treatment for determination of internalised compounds 
 
After washing, cells were treated for 5 min with 30 µL of 0.5 mg/mL trypsin. After 
trypsinization, cells were resuspended in phenol-red free medium and centrifuged for 
5 min at 10,000 g. Cell pellets obtained were then incubated for 20 min with lysis 
buffer prior to a sonication for 5 min. In order to quantify more precisely the 
intracellular compounds, some samples obtained after trypsinization were centrifuged 
for 15 min at 15,000 g. This centrifugation step can eliminate all membrane 
fragments that could have been left after sonication and therefore all compounds 
sticked to the membranes. 
 
Inhibition of the Cathepsin D 
 
Section III.5 
 
Cell Line, Culture and Products 
MDA-MB-231, MCF7, LNCaP, SaOS2 and HCT116 were cultured in DMEM 
containing 10% foetal bovine serum (FBS) (Fisher Scientific, France), 100 U. ml-1 
penicillin and 100 µg.ml-1 streptomycin at 37°C. Pepstatine was from Sigma Aldrich 
Chimie (France).  
Stock solutions of compound were dissolved  at 1 mM in DMSO. For experiment, 
compounds were further diluted with serum-free medium to obtain a final 
concentration of 10-5 M.  
Enzyme kinetic essay  
Section: III.5.2 
Kinetic parameters were determined using the internally quenched fluorescent 
synthetic peptide substrate EDANS–C(O)–CH2–CH2–C(O)–Arg-pro-Ile-Phe-Phe-Arg-
leu-Gln–DABCYL)–OH with a cleavage site of Phe-Phe, previously described by 
Baechle and collaborators.73 The assays were carried out using a Gemini XS 
spectrofluorimeter (Molecular Devices, CA, USA). The excitation and emission 
wavelengths were respectively 335 nm and 538 nm with a cut off at 495 nm. The 
reaction was carried out at 37°C in a solution of 100 mM sodium acetate, 200 mM 
sodium chloride supplemented with 125 µL of NIH3T3 conditioned medium at pH 3.5. 
The observed fluorescence correspond to synthetic substrate hydrolysis by active 
cathepsin D. The fluorescence units were converted to percent of cathepsin D activity 
as a function of total enzyme in vehicle (DMSO).  
 
Cell outgrowth assay  
Section: III.5.3 
Outgrowth assays were performed as described previously.77 Briefly, 5,000 
subconfluent cells were seeded in 96-well plates. The day after seeding, cells were 
treated with the indicated concentration of compounds in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS). 4 days after 
treatment, cells were quantified using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) assay (200 µg/mL MTT for 4 h).  
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Western blot analysis  
Protein extracts were resolved on SDS-PAGE gel and transfered to PVDF-
membrane, which was probed with antibodies against cyclin E (1:500; sc-247, Santa 
Cruz Biotechnology), PCNA (1:500; sc-56, Santa Cruz Biotechnology), cdk-2 (1:500; 
sc-163, Santa Cruz Biotechnology), GAPDH (1:500; ab8245, abcam) and Bcl-2 
(1:500; sc-492, Santa Cruz Biotechnology). The membrane was subsequently 
probed with a horseradish peroxidase-conjugated secondary antibody and developed 
with ECL PLUS (Amersham). 
V.6 MALDI TOF experiments  
 
MALDI-TOF mass spectrometry analysis.  
 
Section III.4.1 
 
The mass spectra were acquired with a Bruker Ultraflex Daltonics instrument (Bruker 
Daltonics, Wissembourg, France). A pulsed Nd:YAG laser at a wavelength of 355 nm 
was operated at a frequency of 100 Hz. External calibration was performed with 
commercial peptide mixture (Calibration peptide standard 2, Bruker Daltonics, 
Wissembourg, France). Data were acquired with the Flex Control software under the 
following MS conditions. The source was operated in the positive mode with an 
acceleration voltage of 25.0 kV and a delayed extraction time of 140 ns was applied. 
The reflectron mode was used for the peptides (voltages of 26.3 kV and 13.9 kV). 
Mass spectra were acquired from 200 laser shots, the laser fluence being adjusted 
for each studied sample (Laser Fluence 1). Ions were detected over a mass range 
from m/z 500 to 3000, the matrix ions being deflected up to m/z 500 to avoid detector 
saturation. 
 
The [D4]HCCA-tagged CPP solubilized in a mixture of acetonitrile/water/trifluoroacetic 
acid (50:50:0.1 v/v/v; 5 mL) at different concentrations was added to the cell sample 
(5 mL). After mixing and centrifugation, the mixture was analyzed by MALDI-TOF 
MS. To improve the signal resolution when the concentration of the internalized 
compound was very low, the mixture was concentrated by lyophilization and 
dissolved in acetonitrile/water/trifluoroacetic acid (50:50:0.1 v/v/v). Each sample was 
analyzed with both the HCCA and the HCCE matrix twice.When the HCCA matrix 
was used, 0.5 mL of the sample was mixed on the MALDI probe with 0.5 mL of the 
matrix solution (half-saturated in acetonitrile/water/trifluoroacetic acid 50:50:0.1 
v/v/v). When the HCCE matrix was used, 0.5 mL of the HCCE matrix (saturated in 
acetone) was deposited and dried on the MALDI probe, and then the peptide solution 
(0.5 mL) was deposited. The isotopic group of peaks of each cell-penetrating 
compound was integrated with the FlexAnalysis software (version 2.2, Bruker 
Daltonics). The SNAP algorithm was used to determine the area of each isotopic 
pattern of light and heavy molecules by calculating their isotopic distribution. 
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V.7 NMR expreriments and structural studies 
The NMR samples of Ac-(DBT)n-NH2 n=[1-8] were prepared by dissolving the 
oligomers in d6-DMSO or CDCl3 (500 μL) at a concentration of 0.5 mM.  
NMR experiments were carried out on a Varian Inova 600 MHz spectrometer, 
equipped with a cryogenic probe optimized for 1H detection. For the one-dimensional 
(1D) 1H spectra, 64 scans were acquired with a spectral width of 6714.8 Hz, 
relaxation delay 1.5 s, 16384 data points for acquisition and 32768 for 
transformation. The 1D spectra in d6-DMSO and CDCl3 were recorded at 
temperature of 298 K. The two-dimensional (2D) [1H,1H] spectra: double quantum 
filtered correlated spectroscopy (DQF-COSY)78, total correlation spectroscopy 
(TOCSY)79, nuclear Overhauser effect spectroscopy (NOESY)80, rotating-frame 
Overhauser effect spectroscopy (ROESY)81, were acquired using the time-
proportional phase-incrementation (TPPI) method to obtain complex data points in 
the t1 dimension. Typically, 32 or 64 scans per t1 increment were collected with a 
spectral width of 6714.8 Hz along both f1 and f2, 2048x256 data points in t2 and t1 
respectively and recycle delay 1.5 s. Only in the case of ROESY the delay was 2s. 
Water suppression in d6-DMSO was achieved by means of Double Pulsed Field 
Gradient Spin Echo (DPFGSE) sequence82. The TOCSY experiment was recorded 
using a DIPSI-2 mixing scheme of 70 ms with 7.7 KHz spin-lock field strength. The 
NOESY spectra were carried out at 298 K with a mixing time in the range of 150 - 
400 ms. The mixing time of the ROESY experiment was in the range of 200 – 350 
ms. The data were typically apodized with a square cosine window function and zero 
filled to a matrix of size 4096x1024 prior to Fourier transformation and baseline 
correction. Chemical shifts were referenced to internal residual signal of the DMSO. 
All NMR data were processed with Varian VNMRJ 1.1.D software and analyzed 
using Monoscope and NEASY83, tools of CARA (http://www.nmr.ch)84.  
 
Experimental distance restraints for structure calculation of Ac-(DBT)6-NH2 were 
derived from the cross-peak volumes in the NOESY spectrum recorded in d6-DMSO 
with a mixing time of 250 ms. NOESY cross-peaks were manually integrated using 
the NEASY software and converted to a target distance constraints according to an 
inverse sixth power peak volume-to-distance relationship: 
 
           
     
           )
 
 
 
As a reference to calculate the ‗Const‘ we used the NOE volume of the interaction 
between HA DBT:B1 and HB2 DBT:B1. The distance between these two atoms was 
estimated at 2.86 Å by the crystallographic data obtained for the DBT monomer.2 
 
The upper limits of the distances were caclulated as target distance plus 15%.  
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V.7.1 Proton chemical shifts of compounds Ac-(DBT)n-NH2  
Chemical shits (in ppm) of Ac-DBT-NH2 protons in DMSO at 25ºC  
First residue (DBT:B1) 
HA HB3 HB2 HD2 HD3  HE1 HZ1 HZ2 HE2 H 
4,491 3,005 3,506 4,658 3,961 7,531 7,585 7,349 7,697 8,446 
 
Chemical Shits (in ppm) of Ac-(DBT)2-NH2 protons in DMSO at 25ºC  
First residue (DBT:B1) 
HA HB2 HB3 HD2 HD3  HE1 HZ1 HZ2 HE2 H 
4,467 3,481 2,977 4,735 4,060 7,455 7,538 7,335 7,673 8,407 
Second residue (DBT:B2) 
4,571 3,533 3,016 4,636 4,048 7,580 7,58 7,373 7,708 8,534 
 
Chemical Shits (in ppm) of Ac-(DBT)3-NH2 protons in DMSO at 25ºC  
First residue (DBT:B1) 
HA HB2 HB3 HD2 HD3  HE1 HZ1 HZ2 HE2 H 
4,453 3,476 2,960 4,737 4,013 7,438 7,519 7,327 7,665 8,385 
Second residue (DBT:B2) 
4,522 3,515 3,007 4,737 4,117 7,471 7,539 7,343 7,682 8,553 
Third residue (DBT:B3) 
4,572 3,525 3,007 4,651 4,048 7,587 7,587 7,378 7,709 8,594 
 
Chemical Shits (in ppm) of Ac-(DBT)4-NH2 protons in DMSO at 25ºC  
First residue (DBT:B1) 
HA HB2 HB3 HD2 HD3  HE1 HZ1 HZ2 HE2 H 
4,486 3,512 2,996 4,775 4,049 7,430 7,509 7,319 7,663 8,356 
Second residue (DBT:B2) 
4,505 3,513 2,976 4,744 4,075 7,459 7,523 7,335 7,674 8,545 
Third residue (DBT:B3) 
4,526 3,527 3,010 4,757 4,104 7,482 7,535 7,351 7,687 8,617 
Fourth residue (DBT:B4) 
4,586 3,527 3,010 4,654 4,052 7,586 7,586 7,372 7,711 8,617 
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Chemical Shits (in ppm) of Ac-(DBT)6-NH2 protons in DMSO at 25ºC  
First residue (DBT:B1) 
HA HB2 HB3 HD2 HD3  HE1 HZ1 HZ2 HE2 H 
4,449 3,471 2,956 4,738 4,009 7,426 7,506 7,304 7,660 8,355 
Second residue (DBT:B2) 
4,498 3,513 2,986 4,744 4,071 7,450 7,501 7,320 7,669 8,524 
Third residue (DBT:B3) 
4,506 3,514 2,986 4,761 4,068 7,467 7,508 7,333 7,675 8,583 
Fourth residue (DBT:B4) 
4,523 3,518 2,991 4,768 4,069 7,469 7,519 7,344 7,680 8,622 
Fifth residue (DBT:B5) 
4,536 3,520 2,999 4,764 4,108 7,482 7,523 7,354 7,690 8,640 
Sixth residue (DBT:B6) 
4,592 3,523 3,004 4,663 4,054 7,591 7,595 7,372 7,708 8,626 
 
V.7.2 Distance restrictions measured for compound Ac-(DBT)6-NH2 from 
2  NOE   e periment performed at 2   C in d6-DMSO 
Table V.7.2 includes NOE interactions detected in the Ac-(DBT)6-NH2 molecule, the 
measured volumes of these interactions and the calculated target distances and upper limits 
(Target distance plus 15%)   
H1 H2 Volume 
Target 
distance  
Uper limit 
(+15%) 
Lower limit 
(-15%) 
HD3 DBT:B1 HB3 DBT:B2 146400 4,9 5,7 4,2 
H DBT:B6 HE1 DBT:B5 311000 4,4 5,0 3,7 
H DBT:B4 HE1 DBT:B3 497500 4,0 4,6 3,4 
H DBT:B5 HE1 DBT:B4 482200 4,0 4,7 3,4 
H DBT:B3 HE1 DBT:B2 373300 4,2 4,9 3,6 
H DBT:B2 HE1 DBT:B1 225800 4,6 5,3 3,9 
HE2 DBT:B1 HB2 DBT:B1 174300 4,8 5,5 4,1 
HE2 DBT:B1 HA DBT:B1 102300 5,2 6,0 4,5 
HE2 DBT:B1 HB3 DBT:B1 91520 5,3 6,1 4,5 
HE2 DBT:B4 HA DBT:B4 173600 4,8 5,5 4,1 
HE2 DBT:B4 HB3 DBT:B4 218300 4,6 5,3 3,9 
HE2 DBT:B4 HB2 DBT:B4 377000 4,2 4,8 3,6 
HA DBT:B4 HB3 DBT:B4 3000000 3,0 3,4 2,5 
HA DBT:B4 HB2 DBT:B4 5000000 2,7 3,1 2,3 
HE1 DBT:B6 HD2 DBT:B6 1852000 3,2 3,7 2,7 
HE1 DBT:B6 HD3 DBT:B6 1743000 3,3 3,8 2,8 
HE1 DBT:B6 HA DBT:B6 125500 5,1 5,8 4,3 
HD3 DBT:B3 HB2 DBT:B4 200000 4,7 5,4 4,0 
HE1 DBT:B2 HB3 DBT:B3 230600 4,6 5,3 3,9 
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HE1 DBT:B2 HB2 DBT:B3 217200 4,6 5,3 3,9 
HE1 DBT:B2 HD2 DBT:B2 3254000 2,9 3,4 2,5 
HE1 DBT:B2 HA DBT:B2 467800 4,1 4,7 3,5 
HE1 DBT:B2 HD3 DBT:B2 3070000 3,0 3,4 2,5 
HZ1 DBT:B3 HD3 DBT:B3 380000 4,2 4,8 3,6 
H DBT:B3 HB3 DBT:B3 2869000 3,0 3,5 2,6 
H DBT:B3 HD2 DBT:B2 4125000 2,8 3,3 2,4 
H DBT:B3 HA DBT:B6 121400 5,1 5,9 4,3 
H DBT:B3 HB2 DBT:B3 1739000 3,3 3,8 2,8 
H DBT:B3 HD3 DBT:B2 3432000 2,9 3,4 2,5 
H DBT:B3 HA DBT:B3 1085000 3,5 4,1 3,0 
HZ1 DBT:B1 HA DBT:B1 76440 5,5 6,3 4,7 
HD2 DBT:B6 HB3 DBT:B6 143900 4,9 5,7 4,2 
HE2 DBT:B2 HB3 DBT:B2 218300 4,6 5,3 3,9 
HE2 DBT:B2 HB2 DBT:B2 377000 4,2 4,8 3,6 
HE2 DBT:B2 HA DBT:B2 173600 4,8 5,5 4,1 
HA DBT:B5 HB3 DBT:B5 3000000 3,0 3,4 2,5 
HA DBT:B5 HB2 DBT:B5 5000000 2,7 3,1 2,3 
HA DBT:B1 HB2 DBT:B1 3854000 2,9 3,3 2,4 
HA DBT:B1 HB3 DBT:B1 2095000 3,2 3,6 2,7 
HE2 DBT:B3 HB3 DBT:B3 218300 4,6 5,3 3,9 
HE2 DBT:B3 HB2 DBT:B3 377000 4,2 4,8 3,6 
HE2 DBT:B3 HA DBT:B3 173600 4,8 5,5 4,1 
HE1 DBT:B4 HA DBT:B4 467800 4,1 4,7 3,5 
HE1 DBT:B4 HB2 DBT:B5 300000 4,4 5,0 3,7 
HE1 DBT:B4 HD3 DBT:B4 3070000 3,0 3,4 2,5 
HE1 DBT:B4 HD2 DBT:B4 3254000 2,9 3,4 2,5 
HE1 DBT:B3 HD3 DBT:B3 3070000 3,0 3,4 2,5 
HE1 DBT:B3 HB2 DBT:B4 300000 4,4 5,0 3,7 
HE1 DBT:B3 HD2 DBT:B3 3254000 2,9 3,4 2,5 
HE1 DBT:B3 HA DBT:B3 467800 4,1 4,7 3,5 
H DBT:B4 HA DBT:B4 1153000 3,5 4,0 3,0 
H DBT:B4 HB3 DBT:B4 2902000 3,0 3,4 2,5 
H DBT:B4 HD3 DBT:B3 3415000 2,9 3,4 2,5 
H DBT:B4 HB2 DBT:B4 1545000 3,3 3,8 2,8 
H DBT:B4 HD2 DBT:B3 3645000 2,9 3,3 2,5 
HZ1 DBT:B6 HA DBT:B6 40230 6,1 7,0 5,2 
HE2 DBT:B5 HA DBT:B5 173600 4,8 5,5 4,1 
HE2 DBT:B5 HB3 DBT:B5 218300 4,6 5,3 3,9 
HE2 DBT:B5 HB2 DBT:B5 377000 4,2 4,8 3,6 
HZ1 DBT:B4 HD3 DBT:B4 380000 4,2 4,8 3,6 
HA DBT:B6 HB3 DBT:B6 3243000 2,9 3,4 2,5 
HA DBT:B6 HB2 DBT:B6 5216000 2,7 3,1 2,3 
HA DBT:B2 HB3 DBT:B2 3000000 3,0 3,4 2,5 
HA DBT:B2 HB2 DBT:B2 5000000 2,7 3,1 2,3 
HZ1 DBT:B2 HD3 DBT:B2 380000 4,2 4,8 3,6 
86 
 
HD3 DBT:B4 HB3 DBT:B5 230000 4,6 5,3 3,9 
HD3 DBT:B4 HB2 DBT:B5 200000 4,7 5,4 4,0 
HD3 DBT:B2 HB3 DBT:B3 230000 4,6 5,3 3,9 
HD3 DBT:B2 HB2 DBT:B3 200000 4,7 5,4 4,0 
H DBT:B5 HA DBT:B5 1475000 3,4 3,9 2,9 
H DBT:B5 HB3 DBT:B5 2902000 3,0 3,4 2,5 
H DBT:B5 HD3 DBT:B4 3415000 2,9 3,4 2,5 
H DBT:B5 HB2 DBT:B5 1545000 3,3 3,8 2,8 
H DBT:B5 HD2 DBT:B4 3645000 2,9 3,3 2,5 
H DBT:B1 HB2 DBT:B1 1104000 3,5 4,1 3,0 
H DBT:B1 HA DBT:B1 845200 3,7 4,2 3,1 
H DBT:B1 HB3 DBT:B1 2121000 3,2 3,6 2,7 
HE2 DBT:B6 HB3 DBT:B6 110400 5,2 5,9 4,4 
HE2 DBT:B6 HB2 DBT:B6 324600 4,3 5,0 3,7 
HA DBT:B3 HB3 DBT:B3 3000000 3,0 3,4 2,5 
HA DBT:B3 HB2 DBT:B3 5000000 2,7 3,1 2,3 
HE1 DBT:B1 HD2 DBT:B1 2349000 3,1 3,6 2,6 
HE1 DBT:B1 HA DBT:B1 151300 4,9 5,6 4,2 
HE1 DBT:B1 HD3 DBT:B1 2038000 3,2 3,7 2,7 
HE1 DBT:B5 HD3 DBT:B5 2761000 3,0 3,5 2,6 
HE1 DBT:B5 HA DBT:B5 467800 4,1 4,7 3,5 
HE1 DBT:B5 HD2 DBT:B5 3254000 2,9 3,4 2,5 
H DBT:B6 HD3 DBT:B5 3415000 2,9 3,4 2,5 
H DBT:B6 HD2 DBT:B5 3645000 2,9 3,3 2,5 
H DBT:B6 HB3 DBT:B6 2902000 3,0 3,4 2,5 
H DBT:B6 HA DBT:B6 987400 3,6 4,1 3,1 
H DBT:B6 HB2 DBT:B6 1545000 3,3 3,8 2,8 
H DBT:B2 HD2 DBT:B1 3597000 2,9 3,3 2,5 
H DBT:B2 HB3 DBT:B2 2623000 3,0 3,5 2,6 
H DBT:B2 HD3 DBT:B1 2884000 3,0 3,5 2,6 
H DBT:B2 HB2 DBT:B2 1361000 3,4 3,9 2,9 
HE1 DBT:B1 HA DBT:B2 87900 5,4 6,2 4,6 
HE1 DBT:B1 HB3 DBT:B2 79020 5,5 6,3 4,6 
HZ2 DBT:B2 HA DBT:B3 47510 6,0 6,8 5,1 
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ABBREVIATIONS 
 
Ac2O - Acetic anhydride 
Ahx - Aminohexanoic acid  
AMPA - 2-aminomethyl-phenyl-acetic acid 
Bcl - B-cell lymphoma  
BH3 - Bcl-2 homology domain 3 
Boc2O - Di-tert-butyl dicarbonate 
BOP - Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate 
CF - Carboxyfluorescein 
CLSM - Confocal Laser Scanning Microscopy 
COSY - Correlation Spectroscopy 
DCM - Dichloromethane 
d - density 
DBT - (3S)-amino-5-(carboxylmethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 
DMF -  Dimethylformamide 
CD - Cathepsin D    
CPNP - Cell Penetrating Non-peptide  
CPP - Cell Penetrating Peptide 
DABCYL - 4-(4-dimethylaminophenylazo) benzoic acid 
DMSO - Dimethyl Sulfoxide  
DIEA - N,N-Diisopropylethylamine 
EDANS - 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid 
ESI - Electrospray Ionisation 
FACS - Fluorescence-activated cell sorting 
FITC - Fluorescein Isothiocyanate  
Fmoc - 9-fluorenylmetoxycarbonyl 
HBTU - O-Benzotriazole-N,N,N‘,N‘-tetramethyl-uronium-hexafluoro-phosphate 
HCCA --cyano-4-hydroxycinnamic acid  
HCCE - cyano-4-hydroxycinnamic methyl ester  
HDM2 – Human MDM2 (murine double minute) 
HPLC - High-Performance Liquid Chromatography 
LBT - (3 R)-amino-5-(carboxylmethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one one     
NMR - Nuclear magnetic resonance  
NOESY – Nuclear Overhauser effect spectroscopy 
m – multiplet   
MALDI-TOF - Matrix-assisted laser desorption/ionization Time  
MS - Mass spectrometry 
MT – Mixing time 
MTT - 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
p53 – Protein 53 
pCD – Preprocathepsin D 
O2Oc - 8-amino-3,6-dioxaoctanoic acid 
OSu - Succinimide 
PMO - Phosphorodiamidate Morpholino Oligo 
PNA - Peptide nucleic acid 
PS – Polystyrene  
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RA – Rink Amide 
RISC - RNA-Induced Silencing Complex 
ROESY - Rotating frame Overhause Effect Spectroscopy 
Rt - retention time 
s – singlet  
SiRNA – small interfering RNA  
SPPS - standard solid phase peptide synthesis 
tBu - Tert-Butyl 
TEA - Triethylamine 
TFA - Trifluoroacetic acid  
TFE - 2,2,2-Trifluoroethanol 
TFEM - Total Fluorescence Emission Measurement  
THF – Tetrahydrofuran 
TIS - Tri-isopropyl-silane 
TLC - Thin Layer Chromatography 
UV – Ultra violet  
Z(Br) - 2-bromobenzyloxycarbonyl 
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